Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021
Efgartigimod IV and SC 
argenx BV Confidential 1TITLE PAGE 
Protocol Title: 
A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, 
Pharmacokinetics, Efficacy, Safety, Tolerability , and Immunogenicity of Multiple Subcutaneous 
Injections of Efgartigimod PH20 SC With Multip le Intravenous Infusions of Efgartigimod in 
Patients With Generalized Myasthenia Gravis  Protocol Number: ARGX-113-2001 
Amendment Number: 1 
Compound:  Efgartigimod 
Brief Title: Evaluating the Pharmacodynamic Noni nferiority of Efgartigimod PH20 
Administered Subcutaneously as Compared to  Efgartigimod Administe red Intravenously in 
Patients With Generalized Myasthenia Gravis  
Study Phase:  3 
Acronym: ADAPT
SC 
Sponsor Name:  [CONTACT_475947]:  
Industriepark Zwijnaarde 7  
9052 Zwijnaarde (Ghent) 
Belgium 
Phone: [PHONE_7242] 00 
Fax: [PHONE_7242] 99 
Regulatory Agency Id entifier Number(s):  
IND:  EudraCT: 2020-004085-19 
Approval Date: [ADDRESS_610266] 2020 
Amendment 1 (02 Jul 2021) 
This amendment is considered to be substantial ba sed on the criteria set fo rth in Article 10(a) of 
Directive 2001/20/EC of the European Parliame nt and the Council of the European Union. 
Overall Rationale for the Amendment: Increase sample size from 46-76 participants to approximately 110 participants. Minor editorial 
changes, including the correction of  typographical errors and format ting inconsistencies, are not 
summarized. 
Protocol Amendment Summary of Changes Table    
Section # and 
Name [CONTACT_475948]: 
Email:   
Toll-free Fax:   The email address and fax number for 
drug safety reporting have been updated. 
1.1 Synopsis 
9.2 Sample Size 
Determination Increase sample size to approximately 110 participants Although 76 participants would provide enough data to establish non-inferiority between SC and IV formulations based on IgG reduction at day 29, the increase 
in sample size to approximately 110 participants will allow better 
quantification of the clinical safety and 
efficacy profile of the SC formulation in patients with gMG while the IV formulation will serve as a reference treatment in this randomized study.  
2.3.1 Efgartigimod Risk Assessment 
Section 11 
References Updated text: 
Participants who are women of 
childbearing potential (WOCBP) must use highly effective or acceptable method of contraception (see inclusion criterion 8  and Section 10.5) The potential risk to teratogenicity/fetotoxicity mitigation strategy was updated to align with the current Investigator’s Brochure (IB) (IB version 9.0). However,  in this protocol 
amendment, the contraception requirements are unchanged from the original protocol dated [ADDRESS_610267] the current version.  
6.8.3 Prohibited 
Medication and 
Procedures Updated text:  
PLEX, Ig therapy (IVIg and SCIg), immunoadsorption, or a change in The text was updated for alignment 
throughout the protocol because any type 
of immunoglobulin therapy, regardless 

Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
 
argenx BV Confidential 4 Section # and 
Name [CONTACT_475949]: of the formulation, is considered rescue therapy.  
8.2.6 Clinical 
Safety 
Laboratory Assessments Updated text: 
The actual sample collection date and 
time must be collected in the participant’s source document and included in the central laboratory data transfer. As the sample collection date and time is 
already collected on the central lab 
requisition forms and loaded into the database from the lab data transfer, there is no need to collect this data on the laboratory assessment eCRF page in duplicate 
10.1.3 Informed Consent Process Updated text: 
Prior to signing the ICF, the study 
participants will be instructed not to participate in any other clinical study that involves a therapeutic intervention until the completion of the study. It is not required to exclude or discontinue participants who are participating in a study that does not involve another intervention because this does not constitute a safety concern for participants. 
10.4.2 Definition of SAE Removed text: 
An SAE is defined as any untoward 
medical occurrence that, at any dose: Is 
a suspected transmission of any 
infectious agent via an authorized 
medicinal product This item does not need to be considered an SAE in this study, and as such this item must be disregarded. 
[IP_ADDRESS] Mandatory Site Visits and Home Visits Removed text: 
If needed, all of the previously listed 
visits can be performed by a home nurse 
except the screening visit. Home nurse services are not a part of this 
study, so this sentence must be disregarded. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
 
argenx BV Confidential 5 TABLE OF CONTENTS 
DOCUMENT HISTORY .............................................................................................................. ...3 
Protocol Amendment Summa ry of Changes Table .........................................................................3  
1. PROTOCOL SUMMARY ..........................................................................................10  
1.1. Synopsis ...................................................................................................................... 10 
1.2. Schema ........................................................................................................................ 15 
1.3. Schedule of Activities .................................................................................................16  
2. INTRODUCTION ......................................................................................................20  
2.1. Study Rationale ...........................................................................................................20  
2.2. Background .................................................................................................................20  
2.3. Benefit/Risk Assessment ............................................................................................21  
2.3.1.  Efgartigimod Risk Assessment ...................................................................................21  
2.3.2.  Efgartigimod Benefit Assessment ..............................................................................22  
2.3.3.  rHuPH20 Risk Assessment .........................................................................................23  
2.3.4.  rHuPH20 Benefit Assessment ....................................................................................24  
2.3.5.  Overall Benefit/Risk Conclusion ................................................................................24  
3. OBJECTIVES AND ENDPOINTS ............................................................................25  
4. STUDY DESIGN .......................................................................................................27  
4.1. Overall Design ............................................................................................................27  
4.2. Scientific Rationale for Study Design ........................................................................27  
4.3. Justification for Dose ..................................................................................................28  
4.4. End of Study Definition ..............................................................................................28  
5. STUDY POPULATION .............................................................................................29  
5.1. Inclusion Criteria ........................................................................................................29  
5.2. Exclusion Criteria .......................................................................................................30  
5.3. Lifestyle Considerations .............................................................................................32  
5.3.1.  Meals and Dietary Restrictions ...................................................................................32  
5.4. Screen Failures ............................................................................................................32  
5.5. Criteria for Temporarily Delaying Admin istration of Study Intervention .................33  
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY ........................34  
6.1. Study Intervention(s)  Administered ...........................................................................34  
6.2. Preparation/Handling/Storage/Accountability ............................................................34  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
 
argenx BV Confidential 6 6.2.1.  Preparation ..................................................................................................................35  
6.2.2.  Handling .....................................................................................................................3 5 
6.2.3.  Storage ........................................................................................................................35  
6.2.4.  Accountability .............................................................................................................35  
6.3. Measures to Minimize Bias: Randomization and Blinding ........................................[ADDRESS_610268] UDY INTERVENTION AND 
PARTICIPANT DISCONTIN UATION/WITHDRAWAL .......................................40  
7.1. Discontinuation of Study Intervention ........................................................................40  
7.2. Participant Discontinuation/W ithdrawal From the Study ...........................................[ADDRESS_610269] to Follow-up .......................................................................................................41  
8. STUDY ASSESSMENTS AND PROCEDURES ......................................................42  
8.1. Efficacy Assessments .................................................................................................42  
8.1.1.  Pharmacodynamics .....................................................................................................42  
8.1.2.  Clinical Efficacy Assessments ....................................................................................42  
[IP_ADDRESS].  MG-ADL ....................................................................................................................42  
[IP_ADDRESS].  QMG ........................................................................................................................... 43 
8.1.3.  Myasthenia Gravis Quality of Life Qu estionnaire (15-item  Scale Revised) ..............43  
8.1.4.  EuroQoL 5 Dimensions 5 Levels ...............................................................................43  
8.2. Safety Assessments .....................................................................................................44  
8.2.1.  Demographics .............................................................................................................44  
8.2.2.  Physical Examinations ................................................................................................44  
8.2.3.  Vital Signs ..................................................................................................................45  
8.2.4.  Electrocardiograms .....................................................................................................45  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
 
argenx BV Confidential 7 8.2.5.  Medical and Surgical History .....................................................................................45  
8.2.6.  Clinical Safety Laboratory Assessments ....................................................................45  
[IP_ADDRESS].  Hematology, Clinical Chemistry, and Urinalysis .......................................................46  
[IP_ADDRESS].  Virus Serology ............................................................................................................47  
[IP_ADDRESS].  Follicle-Stimulating Hormone Level ..........................................................................47  
[IP_ADDRESS].  SARS-CoV-[ADDRESS_610270] ......................................................................................................47  
8.2.7.  Assessment of Admin istration Site .............................................................................47  
8.2.8.  Pregnancy Testing ......................................................................................................47  
8.2.9.  Immunogenicity ..........................................................................................................47  
[IP_ADDRESS].  ADA Against Efgartigimod ........................................................................................47  
[IP_ADDRESS].  ADA Against rHuPH20 ..............................................................................................48  
8.2.10.  Suicidal Ideation and Beha vior Risk Monitoring .......................................................48  
8.3. Adverse Events (AEs), Serious Advers e Events (SAEs), and Other Safety 
Reporting ....................................................................................................................[ADDRESS_610271] .............................................................................51  
8.4. Pharmacokinetics ........................................................................................................51  
8.5. Genetics and/or Pharmacogenomics ...........................................................................52  
8.6. Biomarkers ..................................................................................................................52  
8.7. Immunogenicity Assessments ....................................................................................52  
8.8. Medical Resource Utilizati on and Health Economics ................................................52  
8.9. Storage of Blood Samples After the Study .................................................................52  
9. STATISTICAL CONSIDERATIONS .......................................................................54  
9.1. Statistical Hypotheses .................................................................................................54  
9.2. Sample Size Determination ........................................................................................54  
9.3. Analysis Sets ...............................................................................................................56  
9.4. Statistical Analyses .....................................................................................................56  
9.4.1.  General Considerations ...............................................................................................57  
9.4.2.  Primary Endpoint ........................................................................................................57  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
 
argenx BV Confidential 8 9.4.3.  Secondary Endpoints ..................................................................................................58  
9.4.4.  Exploratory Endpoints ................................................................................................58  
9.5. Interim Analysis ..........................................................................................................58  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..................................................................................................59  
10.1.  Appendix 1: Regulatory, Ethical, an d Study Oversight Considerations ....................59  
10.1.1.  Regulatory and Ethical Considerations ......................................................................59  
10.1.2.  Financial Disclosure ...................................................................................................59  
10.1.3.  Informed Consent Process ..........................................................................................60  
10.1.4.  Data Protection ...........................................................................................................61  
10.1.5.  Committees Structure .................................................................................................61  
[IP_ADDRESS].  Data Safety Monitoring Board ....................................................................................61  
10.1.6.  Dissemination of Clinical Study Data ........................................................................62  
10.1.7.  Data Quality Assurance ..............................................................................................62  
[IP_ADDRESS].  Data Handling and Record Keepi[INVESTIGATOR_007] ...........................................................................63  
[IP_ADDRESS].  Quality Assurance Audit .............................................................................................63  
[IP_ADDRESS].  Quality Control ...........................................................................................................63  
10.1.8.  Source Documents ......................................................................................................64  
10.1.9.  Study and Site Start and Closure ................................................................................65  
10.1.10.  Publication Policy .......................................................................................................65  
10.2.  Appendix 2: Clinical Laboratory Tests .......................................................................67  
10.3.  Appendix 3: Total Blood Volume Collected From Each Participant .........................69  
10.4.  Appendix 4: AEs and SAEs: Definiti ons and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ........................................................................70  
10.4.1.  Definition of AE .........................................................................................................70  
10.4.2.  Definition of SAE .......................................................................................................71  
10.4.3.  Recording and Follow-up of AEs and/or SAEs ..........................................................71  
10.4.4.  Reporting of SAEs ......................................................................................................73  
10.5.  Appendix 5: Contraceptive and Barrier Guidance ......................................................74  
10.5.1.  Definitions ..................................................................................................................74  
10.6.  Appendix 6: Administrative Structure ........................................................................77  
10.7.  Appendix 7: Possible Adaptations to  Study Protocol Du ring the COVID-19 
Pandemic .....................................................................................................................7 9 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
 
argenx BV Confidential 9 10.7.1.  COVID-19 Risk Assessment for Participant Safety ...................................................79  
10.7.2.  COVID-19 Risk Mitigation ........................................................................................79  
10.7.3.  Possible Changes in Study Design Due to the COVID-19 Pandemic ........................80  
[IP_ADDRESS].  Implementation of This Appendix ..............................................................................80  
[IP_ADDRESS].  Testing for COVID-19 ................................................................................................80  
[IP_ADDRESS].  Study Protocol Changes ..............................................................................................80  
[IP_ADDRESS].  Critical Parameters to Be Collected During the Study ...............................................80  
[IP_ADDRESS].  Mandatory Site Visits and Home Visits .....................................................................80  
10.8.  Appendix 8: Interpretation of Hepatitis B Serologic Test Results .............................82  
10.9.  Appendix 9: Abbreviations and Definitions ...............................................................[ADDRESS_610272] OF TABLES 
Table 1:  Schedule of Activitie s for Study ARGX-113-2001 ....................................................16  
Table 2:  Analysis Sets ...............................................................................................................56  
Table 3:  Protocol-Required Laboratory Tests ...........................................................................68  
Table 4:  List of Vendor Information .........................................................................................[ADDRESS_610273] OF FIGURES 
Figure 1:  Schema for Study ARGX-113-2001 ...........................................................................15  
Figure 2:  Statistical Modeling on MG-ADL Change From Baseline With IgG Percent 
Reduction From Baseline as a Predictor and Patient as a Random Effect in 
All Efgartigimod IV Treated Pa tients in Study ARGX-113-1704 (mITT 
Analysis Set) ...............................................................................................................55  
 
 
 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
 
argenx BV Confidential 10 1. PROTOCOL SUMMARY 
1.1. Synopsis 
Protocol Title: 
A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, 
Pharmacokinetics, Efficacy, Safety, Tolerability , and Immunogenicity of Multiple Subcutaneous 
Injections of Efgartigimod PH 20 SC With Multiple Intravenou s Infusions of Efgartigimod in 
Patients With Generalized Myasthenia Gravis 
Brief Title:  Evaluating the Pharmacodynamic Noninf eriority of Efgartigimod PH20 SC 
Administered Subcutaneously as Compared to  Efgartigimod Administe red Intravenously in 
Patients With Generalized Myasthenia Gravis   
Rationale: The aim of this study is to investigate th e pharmacodynamics (PD), pharmacokinetics (PK), 
safety, tolerability, immunogenici ty, and clinical efficacy of efgartigimod coformulated with 
recombinant human hyaluronidase PH20 (rHuP H20) administered subcutaneously (SC) 
(efgartigimod PH20 SC) as compar ed to efgartigimod intravenous ly (IV) infused (efgartigimod 
IV) in patients with generalized myasthenia gravis (gMG). Objectives and Endpoints:  
Objectives Endpoints 
Primary  
x To demonstrate that the PD effect of 
injections of 1000 mg efgartigimod PH20 SC, administered once per week (q7d) for 
4 administrations, is non inferior to that of 
IV infusions of efgartigimod at a dose of 
10 mg/kg administered q7d for 4 
administrations. x Percent reduction from baseline in total 
immunoglobulin G (IgG) levels at day 29, ie, [ADDRESS_610274] of efgartigimod 
PH20 SC and efgartig imod IV over time x Absolute values, change from baseline, and percent reduction from baseline in 
total IgG levels over time 
x Absolute values, change from baseline, 
and percent reduction from baseline in 
acetylcholine receptor binding autoantibodies (AChR-Ab) levels over 
time in AChR-Ab positive patients 
x Absolute values, change from baseline, 
and percent reduction from baseline in 
IgG subtype levels (IgG1, IgG2, IgG3, 
and IgG4) over time  
x Area under the effect curve (AUEC) of 
the percentage reduction from baseline 
total IgG and similar AUEC for each IgG subtype per dosing interval (days 1–8, 
days 8–15, days 15–22, and days 22–29), 
days 1–29, and over the entire study (days 1–71)
 
x To evaluate the PK of efgartigimod PH20 
SC and efgartigimod IV x PK parameters: maximum concentration (C
max) (after all doses for the IV 
treatment arm), concentration observed 
predose (C trough) 
x To evaluate the safe ty, tolerability, and 
immunogenicity of efgartigimod PH20 
SC and efgartigimod IV x Incidence and prevalence of anti-drug 
antibodies (ADAs) against efgartigimod  
x Incidence and prevalence of ADAs against rHuPH20 in the SC treatment arm 
x Incidence and severity of adverse events 
(AEs), incidence of serious adverse 
events (SAEs), and changes in laboratory test results, physical examination results, 
vital signs, and electrocardiogram (ECG) 
results 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
 
argenx BV Confidential 13 Brief Summary: 
The purpose of this study is to investigate th e PD, PK, safety, tolerability, immunogenicity, and 
clinical efficacy of efgartigimod coformulat ed with recombinant hum an hyaluronidase PH20 
(rHuPH20) as compared to efga rtigimod IV infused in patients with gMG to evaluate the PD 
noninferiority of the SC formulation compared  to the intravenous formulation. Study details 
include: Study Duration: 12 weeks Treatment Duration: 3 weeks 
Health Measurements: To tal levels of immunoglobulin G (IgG) , levels of IgG subtypes, AChR-
Ab levels, MG-ADL, QMG 
Visit Frequency: Every week th rough visit 9, followed by a 2-week period between visit 9 and 
the end of the study visit Number of Participants: Approximately 110 participants will be enrolled a nd randomized in a 1:[ADDRESS_610275] ration for efgartigimod. See also 
Section 9.2. Randomization will be stratified by [CONTACT_475904]-Japanese participants. 
Within non-Japanese participants , randomization will be  further stratified by [CONTACT_475905]-Ab status. 
Up to 20% of participants included in the study will be AChR-Ab seronegative Japanese and up 
to 20% will be AChR-Ab serone gative non-Japanese patients. 
Note : “Enrolled” means a participant,  or their legally acceptable representative, has agreed to 
participate in a clinical study following comp letion of the informed  consent process and 
screening. Potential participants screened to  determine study eligibility but who do not 
participate in the study are not considered enrolled unless otherwise specified by [CONTACT_760]. 
“Randomized” means that an enro lled participant has been randomly assigned to a treatment 
arm. Intervention Groups and Duration: The study duration is approximately 12 we eks, spanning the following study periods: 
x screening period: approx imately [ADDRESS_610276] been received 
x treatment period: 3 weeks 
x follow-up period: 7 weeks 
On day 1, participants will be randomized to receive either efgartigimod IV 10 mg/kg or 
efgartigimod PH20 SC 1000 mg during the treatment period. All par ticipants will receive a total 
of 4 administrations of the assigned IMP, admin istered q7d. Participants receiving efgartigimod 
PH20 SC 1000 mg or their caregivers will be traine d to administer the IMP. Participants will be 
discontinued from treatment if it is in the participant’s best interest, as determined by [CONTACT_151779]. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
 
argenx BV Confidential 14 Data Monitoring/Other Board:  Yes (see Section [IP_ADDRESS])  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 15  1.2. Schema 
Figure 1: Schema for Study ARGX-113-2001 
 
EoS=end of study; gMG=generalized myasthenia gravis; IMP=investigational medicinal product; IV=intravenous(ly); PH20=rHuPH20 (r ecombinant human 
PH20 hyaluronidase); SC=subcutaneous; V=visit 
a Participants will be randomized in a 1:1 ratio to either the efgartigimod IV 10 mg/kg treatment arm or the efgartigimod PH20 S C 1000 mg treatment arm. 
Participants will receive IMP every 7 days for 4 administrations. 
b Participants receiving efgartigimod PH20 SC or their caregivers will be trained in self-administration of the IMP. Once a part icipant or caregiver is considered 
competent to self-administer, they will be allowed to self-admin ister the IMP on site under supervision of the site staff start ing at V2. 
c The follow-up period consists of weekly visits through V9, followed by a 2-week period between V9 and EoS. 

Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 16  1.3. Schedule of Activities  
Table 1: Schedule of Acti vities for Study ARGX-113-2001 
  
Screening Treatment Period Follow-up Period End 
of 
Study Unscheduled 
Visit  
V1 
Baseline V2 V3 V4 V5 V6  V7 V8 V9 EoSa UNSb 
Study Day (visit window) -14 
to  
-1  1 8(±1) 15(±1) 22(±1) 29(±2) 36(±2) 43(±2) 50(±2) 57(±2) 71(±3)  
Activity 
Informed consentc X            
Inclusion/exclusion 
criteria X X           
SARS-CoV-2 testd X            X  
Medical/surgical historye X            
Demographic data X 
Height and weightf X X         
X X 
MG-ADL X X X X X X X X X X X X 
QMGg X X X X X X X X X X X 
MG-QoL15r  X         X  
EQ-5D-5L  X         X  
Physical examination X X X X X X X X X X X X 
Vital signsh X X X X X X X X X X X X 
SIB risk monitoringi X X X X X X X X X X X X 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 17    
Screening Treatment Period Follow-up Period End 
of 
Study Unscheduled 
Visit V1 
Baseline V2 V3 V4 V5 V6  V7 V8 V9 EoSa UNSb 
Study Day (visit window) -14 
to  
-1  1 8(±1) 15(±1) 22(±1) 29(±2) 36(±2) 43(±2) 50(±2) 57(±2) 71(±3)  
Activity 
Clinical laboratory testsj X X X X X X X X X X X X 
AChR-Ab serotype X 
Single 12-lead ECGk X X   
X      
X X 
Urinalysis X X   X X     X X 
Pharmacokineticsl X X X X X X X X X X X 
Pharmacodynamicsm  
X X X X X X X X X X X 
Immunogenicityn X X X   X X X 
Pregnancy testo X X X X X X     
X X 
Viral screenp X            
Randomizationq  
X           
Training for self-
administration of SC IMPr  X X X X (X) (X) (X) (X) (X) (X) (X) 
Administration of IMPs X Xt Xt Xt 
Assessment of administration site
u Continuous monitoring 
Hospi[INVESTIGATOR_475896]
v Continuous monitoring 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 18    
Screening Treatment Period Follow-up Period End 
of 
Study Unscheduled 
Visit V1 
Baseline V2 V3 V4 V5 V6  V7 V8 V9 EoSa UNSb 
Study Day (visit window) -14 
to  
-1  1 8(±1) 15(±1) 22(±1) 29(±2) 36(±2) 43(±2) 50(±2) 57(±2) 71(±3)  
Activity 
Prior/concomitant 
therapyv Continuous monitoring 
Adverse eventsv Continuous monitoring 
Ab= antibody; AChR-Ab=acetylcholine receptor binding autoantibody;  AChE=acetylcholinesterase; ADA=anti-drug antibodies; ECG=ele ctrocardiogram; EoS=end of study; 
EQ-5D-5L=EuroQoL 5 Dimensions 5 Levels; ER=emergency room; FSH= follicle-stimulating hormone; ICU=intensive care unit; IgG=immu noglobulin G; 
IMP=investigational me dicinal product; IV=intravenous; MG-ADL =Myasthenia Gravis-Activ ities of Daily Living total score; MGFA=My asthenia Gravis Foundation of 
America; MG-QoL15r=Myasthenia Gravis Quality of Life Questi onnaire (15 item scale revised); NAb =neutralizing antibody; PD=pharmacodynamics; PHQ=Patient Health 
Questionnaire; PK=pharmacokinetics; PR= atrioventricular node delay interval; QMG=Quantitative My asthenia Gravis score; QRS=dur ation of ventricular depolarization; 
QT=total duration of ventricular depolarization; QTcF=rate-correc ted QT intervals using Frideric ia’s formula; PH 20= recombinant  human hyaluronidase PH20 (rHuPH20); 
RR= time between heartbeats; SARS-CoV-2=severe acute respi[INVESTIGATOR_179893] 2; SC=subcutaneous; SIB=Suicide Ideation and Behavior; SoA=Schedule of 
Activities; UNS=unscheduled; V=visit 
Note: All activities are performed  predose on dosing days unless othe rwise indicated. It is reco mmended to perform the MG-ADL s cale prior to all other assessments. 
a After a participant completes the study and all EoS visit activit ies, the participant will be allowed, if eligibility criteria are met, to roll over into the open-label extension study 
ARGX-113-[ADDRESS_610277] of the participant or the investigator. During the UNS visit, activities as indicated in the SoA can be performed at the discretion of the 
investigator, depending on the reason for the UNS visit. 
c No study-related activities will be  initiated before the participan t signs the informed consent form. 
d A nasopharyngeal swab will be performed to sample nasal and throat mucosal cell s. Participants may be retested as needed (see Section 10.7) 
e Medical history will also include all ER visits, hospi[INVESTIGATOR_602] , and ICU admissions that have occurred in the previous [ADDRESS_610278] 12 hours before the QMG assessment (consistent with the revised manual for the Q MG test as recommended by [CONTACT_475906]). 
h It is recommended that the method used to measure body temperature at screening is maintained throughout the study for each pa tient. 
i The SIB Risk Monitoring assessment is ba sed on question 9 of the PHQ. See Section 8.2.10. 
j Blood samples for clinical laboratory (hemato logy/clinical chemistry and FSH, if applicable) safety assessments will be collec ted predose on dosing days. In addition, total IgG 
at screening is to be assessed for defining eligibility. Particip ants need to be in a fasted state (defined as no food or drink , except for water, which is allowed until at least 4 hours 
prior to sampling) for at least 8 hours prior to each sampling.  
k The following ECG intervals will be measured: RR, PR, QRS, QT, and QTcF. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 19  l On dosing days, PK samples will be collected predose (within 1 hour prior to start of administration) and at the end of each i nfusion for IV (within 1 hour after end of infusion). 
No postdose PK samples will be collected in  case of IMP administration by [CONTACT_10530]. 
m The PD analysis comprises levels of total IgG, IgG subtypes (IgG1, IgG2, IgG3 and IgG4) and levels of AChR-Abs (for AChR-Ab seropositive participants only). 
n Titers of ADA against efgartigimod and presence of NAbs against efgartigimod will be  measured in serum in both the IV and SC t reatment arms. Plasma titer levels of ADA and 
NAbs against rHuPH20 will be measured in the SC treatment arm only. 
o Female participants of childbearing potentia l will be tested for pregnancy using a seru m test at screening and a urine test at  all other visits. 
p The virology screen includes relevant te sts to comply with exclusion criteria [ADDRESS_610279] result is not 
available in time  (ie, within the 2 weeks screening window), the screening window can be in creased by a maximum of 5 calendar d ays as needed. 
r Applicable to participants in the SC tr eatment arm only. These participants and th eir caregivers will be trained in self-admin istration of efgartigimod PH 20 SC and the training 
can continue until the participant or their caregiver is capable of self-a dministration. Training sess ions marked with parenthe ses “(X)” are optional. 
s The IMP (efgartigimod IV or efgartigimod PH20 SC) will be administ ered at visits 1, 2, 3, and [ADDRESS_610280] 1 hour following the end of th e drug administration to be monitored for safety. 
t Participants randomized to the SC treatment arm or their careg ivers will be allowed to administer efgartigimod PH20 SC at the site under supervision if the self-
administration/caregiver-supported administration training is completed and documente d and if the site staff determine that the  participant is ready to do so. 
u The assessment of the administration site will be performed prior to dosing and [ADDRESS_610281]  study-related activity. Relevant prior therapy and all available vaccination his tory will only be collected at screening. See 
Section 6.8 and Section 8.3. 
 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 20  2. INTRODUCTION 
Efgartigimod is a human immunoglo bulin (Ig) G1 (IgG1)-derived Fc  fragment that binds with 
nanomolar affinity to human Fc Rn that is being developed fo r the treatment of generalized 
myasthenia gravis. 
2.1. Study Rationale 
The aim of this study is to investigate th e pharmacodynamics (PD), pharmacokinetics (PK), 
safety, tolerability, immunogenici ty, and clinical efficacy of efgartigimod coformulated with 
recombinant human hyaluronidase PH20 (rHuPH20, brand name [CONTACT_475950]®) administered 
subcutaneously (SC) (efgartigimod PH20 SC) as  compared to efgartigimod intravenously (IV) 
infused (efgartigimod IV) in patients with  generalized myasthenia gravis (gMG).  
The PD of efgartigimod IV at 10 mg/kg and efgartigimod PH20 SC  at a fixed dose of 1000 mg 
will be evaluated, as per the primary objective. The SC formulation of efgartigimod will include 
rHuPH20 because the enzyme allo ws manual SC injection within a few minutes and using larger 
volumes than what is possible without rHuPH20.  
2.2. Background 
gMG is a rare, chronic, neuromuscular autoimmune disease caused by [CONTACT_475907] (NMJ), produci ng reduced neuromuscular transmission and 
debilitating and potentially life -threatening muscle weakness a nd chronic fatigue. Generalized 
muscle weakness results in difficulties in mo bility, speech, swallowing, vision, and respi[INVESTIGATOR_1516]. 
Up to 20% of patients develop potentially life-threatening myasthen ic crisis involving respi[INVESTIGATOR_475897].1,2 
ARGX-113 (efgartigimod) is an investigational antibody fragment  and a first-in-class neonatal 
Fc receptor (FcRn) antagonist that is being eval uated for the treatment of  patients with severe 
autoimmune diseases mediated by [CONTACT_475908] , including gMG. 
Approximately 90% of patients wi th gMG have detectable levels  of IgG autoantibodies in the 
serum. Most commonly, these antibodies are against the acetylcholine receptor (AChR).[ADDRESS_610282] from the IgG binding 
site. 
Efgartigimod is a human IgG1 antibody Fc fragm ent, a natural ligand of  FcRn, engineered for 
increased FcRn affinity at both physiologica l and acidic pH. Efgartigimod outcompetes 
endogenous IgG binding, preventing FcRn-mediate d recycling of IgGs  and increasing IgG 
degradation.  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 21  In the phase 3 study ARGX-113-1704 in patients w ith gMG, treatment with efgartigimod IV 
resulted in a statistically signi ficant increase in the percentage of partic ipants responding to 
treatment based on the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score and 
the Quantitative Myasthenia Gravis (QMG) sc ore as compared to placebo. Additionally, 
efgartigimod IV treatment resulted in a substantial mean percent decrease in total IgG levels as 
compared to no observable change in particip ants who received placebo, which further supported 
the results of the phase [ADDRESS_610283] ed in healthy subjec ts in study ARGX-113-1901, 
which resulted in a dose-dependent decrease in total IgG levels. 
A detailed description of the chemistry, pharmacology, efficacy, a nd safety of efgartigimod is 
provided in the Investigator’s Brochure (IB). Fo r more information on rHuPH20, refer to the IB 
for rHuPH20. 
2.3. Benefit/Risk Assessment 
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events (AEs) of efgartigimod  may be found in the IBs for efgartigimod4 and 
rHuPH205.  
2.3.1. Efgartigimod Risk Assessment 
Overall, efgartigimod IV has been well tolerated in healthy participants subjects as well as in 
patients with gMG. Efgartigimod PH20 SC was well tolerated in healthy participants. No major 
safety findings have arisen in ongoing and completed studi es with either formulation of 
efgartigimod. Further information can be found in the IB4. 
Potential Risk of Clinical 
Significance Summary of Data/Rationale 
for Risk Mitigation Strategy 
Study Intervention (s) 
Immune modulation leading to 
increased infection risk Efgartigimod reduces IgG levels, potentially hindering immune response and increasing the infection risk. However, no 
opportunistic infection with 
efgartigimod has been observed. Efgartigimod treatment may be associated with a small increase in the frequency of infections. 
However, the type and severity 
of these infections are not different to those which patients with gMG are ordinarily susceptible. There is no increase in the type of infectious events 
that might be expected from 
high degrees of 
immunosuppression Participants with clinically 
significant uncontrolled infections, malignancies, recent surgeries, and/or the presence of 
certain viral infections are 
excluded (see Section 5.2). 
Administration of efgartigimod to a participant will be interrupted if a clinically 
significant infection occurs. 
Infections are considered an adverse event of special interest (AESI) and a detailed questionnaire will be completed for any infectious events.  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 22  Potential Risk of Clinical 
Significance Summary of Data/Rationale 
for Risk Mitigation Strategy 
Study Intervention (s) 
(eg, tuberculosis or 
opportunistic infections).  
Injection and/or infusion-related reactions (IRRs) All therapeutic proteins have the potential to elicit antibody or other immune or nonimmune mediated responses, potentially resulting in hypersensitivity or allergic reactions such as rash, 
urticaria, angioedema, serum 
sickness, and anaphylactoid or anaphylactic reactions. 
None of the participants treated 
with either efgartigimod 
formulation had a treatment-emergent adverse event (TEAE) that was a drug hypersensitivity or anaphylactic reaction Participants will be monitored at the site for 1 hour after administration and administration site reactions will be monitored continuously (see Section 1.3). 
Potential risk to teratogenicity/fetotoxicity No clinical studies have been performed to evaluate reproductive risks. However, 
nonclinical studies performed 
suggest that there is no risk of teratogenicity or fetotoxicity. Pregnant women are excluded. Participants who are women of childbearing potential 
(WOCBP) must use a highly 
effective or acceptable method of contraception (see inclusion 
criterion 8 and Section 10.5
) 
2.3.2. Efgartigimod Benefit Assessment 
Efgartigimod has been shown to effectively redu ce IgG antibodies in se veral clinical studies, 
including in healthy subjects, patients with immune thromboc ytopenia (ITP), patients with 
pemphigus vulgaris, and patient s with gMG (see the IB). Patients with gMG also saw 
improvements in gMG symptoms and quality of life. Studies involving patients with gMG are 
described in the following text. 
x A phase 2 study (ARGX-113-1602) enrolled  patients with gMG that were 
seropositive for AChR bindi ng autoantibodies (AChR-Ab) and had an MG-ADL total 
VFRUH RI  ZLWK PRUH WKDQ  RI WKLVVFRUHDWWULEXWHGWRQRQR FXODULWHPV
Participants received efgartigimod IV 10  mg/kg or placebo q 7d for 4 infusions.  
 Efgartigimod IV showed statistically si gnificant improvements as compared to 
placebo in clinical evaluations of MG symptoms, including the MG-ADL and the 
QMG. 
 The efgartigimod IV treatment arm showed a substantial percent reduction from 
baseline in total IgG levels as compared  to the placebo arm, where no discernable 
difference from ba seline was observed. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 23   Efgartigimod IV was safe and well tolera ted, with all treatment-emergent adverse 
events (TEAEs) classified as mild or moderate. 
x A phase 3 study (ARGX-113-1704) enrolled patients with gMG with an MG-ADL 
WRWDO VFRUH  ZLWK PRUHWKDQRIWKHWRW DOVFRUHFRPLQJIUR P QRQRFXODU
symptoms, regardless of AChR-Ab presence in the serum. Participants received 
efgartigimod IV 10 mg/kg or placebo q7d for 4 infusions, with additional treatment 
cycles allowed based on the clinical respon se of the participant as evaluated by [CONTACT_475909]-ADL total score. 
 The efgartigimod IV treatment arm had a statistically significantly higher 
percentage (67.7%) of MG-ADL responde rs as compared to the placebo arm 
(29.7%) among AChR-Ab positive patients. In the overall population (AChR-Ab 
positive and AChR-Ab negative participants),  the efgartigimod treatment arm also 
reported a significantly higher percenta ge of MG-ADL responders (67.9%) 
compared to the pl acebo arm (37.3%). 
 The efgartigimod IV treatment arm had a statistically significantly higher 
percentage of QMG responders (63.1%) as compared to the placebo arm (14.1%) 
among AChR-Ab positive participants.  
 In the AChR-Ab seropositive population, the maximum mean percent change 
from baseline in total IgG levels was approximately 61% [ADDRESS_610284] infusion of a treatment cycle. No substantial mean percent change in total IgG 
levels from baseline was observed in the placebo arm. The results were 
comparable between AChR-Ab seropos itive participants and the overall 
population. 
 Efgartigimod IV 10 mg/kg q7d was safe a nd well tolerated. Th e efgartigimod IV 
arm had a lower percentage  of participants reporti ng TEAEs than the placebo 
arm. The majority of TEAEs reported we re mild or moderate in severity. 
2.3.3. rHuPH20 Risk Assessment 
More information on the use of rHuPH20 (brand name [CONTACT_475950]) is available in the rHuPH20 
IB
5. 
SC injections were well tolerated in healthy subjects, dehydrated pediat ric patients, hospi[INVESTIGATOR_475898], patient s with type 1 and 2 diabetes, and patients with rheumatoid 
arthritis. SC injections of rHuPH20 alone or in combination with lactated Ringer’s solution, 
normal saline, co-injected drugs (eg, morphine, ceftriaxone, ondans etron), peptides (eg, insulin 
and insulin analogs), or proteins (IgG and adalimu mab) have been well tolerated in all clinical 
studies. 
Most AEs observed were mild, transient injec tion site reactions, incl uding erythema, pain, 
bruising, pruritus, burning, tendern ess, edema, indurati on, irritation, paresthesia, numbness, and 
rash. Moderate injection site reactions, wh ich occurred less frequently, include burning, 
erythema, pain, and numbness. Mild-to-m oderate headache was also reported.  
Hylenex prescribing information as of Februa ry 2016 contains the following warnings and 
precautions: 
Clinical Study Protocol  ARGX-113-[ADDRESS_610285], and 
associated clinical benefit. Th is formulation and SC  administration are expected to improve 
patient convenience as compared to the IV formulat ion, as participants or th eir caregivers will be 
permitted to administer ef gartigimod PH20 SC once they  are competent to do so. 
2.3.5. Overall Benefit/Risk Conclusion 
Taking into account the measures ta ken to minimize risk to study pa rticipants, the potential risks 
identified in association with efgartigimod and rHuPH20 are justif ied by [CONTACT_475910]. 
Clinical Study Protocol  ARGX-113-[ADDRESS_610286] of 
injections of 1000 mg efgartigimod PH20 SC, administered once per week (q7d) for 
4 administrations, is non inferior to that of 
IV infusions of efgartigimod at a dose of 
10 mg/kg administered q7d for 
[ADDRESS_610287] of efgartigimod PH20 SC and efgartig imod IV over time x Absolute values, change from baseline and percent reduction from baseline in 
total immunoglobulin (IgG) levels over 
time 
x Absolute values, change from baseline 
and percent reduction from baseline in 
AChR-Ab levels over time in AChR- Ab positive patients 
x Absolute values, change from baseline, and percent reduction from baseline in IgG subtype levels (IgG1, IgG2, IgG3, 
and IgG4) over time  
x Area under the effect curve (AUEC) of 
the percentage reduction from baseline 
total IgG and similar AUEC for each IgG 
subtype per dosing interval (days 1–8, days 8–15, days 15–22, and days 22–29), 
days 1–29, and over the entire study 
(days 1–71)
 
x To evaluate the PK of efgartigimod PH20 SC and efgartigimod IV x PK parameters: maximum concentration (C
max) (after all doses for the IV 
treatment arm), concentration observed predose (C
trough) 
Clinical Study Protocol  ARGX-113-[ADDRESS_610288] of efga rtigimod PH20 SC 1000 mg as compared to 
efgartigimod IV 10 mg/kg in patients with gMG. The sa fety, clinical efficacy, 
immunogenicity, PK of efgartigimod PH20 SC  1000 mg and efgartigimod IV 10 mg/kg 
will also be assessed. 
x The total study duration is  approximately 12 weeks: 
o approximately [ADDRESS_610289] been received 
o 3 weeks of treatment 
o 7 weeks of follow-up 
x The primary target population is adult patien ts with generalized myasthenia gravis 
(gMG), who have an MG-ADL total score  points and greater than 50% of the total 
score attributed to nonocular symptoms, at sc reening and baseline. Participants must be 
receiving a stable dose of c oncomitant treatment for gMG. 
x Serum from participants will be  tested to determine their AChR-Ab status. Up to 20% of 
the participants randomized can be ser onegative for AChR-Abs  in both the overall 
population and the Japanese  participant population.  
x Randomization will be stratified by [CONTACT_475911]-Japanese participants. Within 
non-Japanese participants, randomization will be further stratified  by [CONTACT_475905]-Ab status. 
x After confirmation of eligibility, participants will be randomized 1:1 at the day 1 visit to 
receive efgartigimod IV  10 mg/kg or efgartigimod PH20 SC 1000 mg every 7 days (q7d) 
for [ADDRESS_610290] and/or fourth injectio ns at the site under supervision. 
x At End of Study (EoS), eligible participants will be offered the option to roll over into a 
single-arm extension study ARGX-113- 2002 to receive efgartigimod PH20 SC. 
Participants who complete this  study may be eligible to part icipate in the extension study. 
4.2. Scientific Rationale for Study Design 
The aim of this study is to assess the PD, PK, sa fety, tolerability, immunogenicity, and clinical 
efficacy of efgartigimod coadmin istered with rHuPH20 subcutan eously (efgartigimod PH20 SC) 
as compared to efgartigimod IV in patients with gMG. IgG autoantibodies lead to gMG 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 28  symptoms, resulting from destruction of importa nt molecules in the NMJ, including AChR. IgG 
antibody total levels, levels of IgG subtypes (IgG1, IgG2, IgG3, and IgG4), and levels of AChR-
Abs will be evaluated as an objective surrogat e measure for gMG treatment efficacy, as study 
ARGX-113-1704 showed that reduction total IgG levels and AChR-Ab levels (in AChR-Ab 
seropositive participants) correlat e with reductions in the MG-ADL total score. Clinical efficacy 
will be measured by [CONTACT_258972]-ADL total score an d the QMG score, which are well-established 
measures for assessing disease severity. 
The PD of efgartigimod IV at  10 mg/kg and efgartigimod PH20 SC at a fixed dose of 1000 mg 
will be compared, as per the primary  objective of this study (see Section 3). The SC formulation 
of efgartigimod will include rHuP H20 because the enzyme facilita tes the SC delivery of volumes 
greater than ~[ADDRESS_610291] of the secondary endpoints. Importantl y, a double blind study design would be more 
burdensome for the participants. 
4.3. Justification for Dose 
The selection of the efgartig imod IV dosage (10 mg/kg q7d) wa s made based on results from 
prior clinical studies, includi ng a phase 3 study in particip ants with gMG (ARGX-113-1704). 
Administration of efgartigimod IV 10 mg/kg q7d for [ADDRESS_610292] ed targets a similar total IgG reduction as compared to the 
efgartigimod IV 10 mg/kg dose, anticipating a similar clinical response. PK/PD modeling 
indicated that weekly or biweekly doses of efgartigimod PH20 SC  [ADDRESS_610293] on IgG levels when compared to efgartigimod IV 10 mg/kg administered q7d 
or biweekly (q2w).  
No safety concerns have been identified to date  with SC administration of efgartigimod PH20 SC 
in the completed phase [ADDRESS_610294] co mpleted the study if he/she 
completed the EoS visit at day 71 (±3 days), even if the participant did not complete treatment. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 29  5. STUDY POPULATION
Prospective approval of protocol deviations to recruitment and en rollment criteria, also known as 
protocol waivers or exem ptions, is not permitted. 
5.1. Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria apply: 
Must be capable of giving signed informed consent as described in  Section 10.1, which
includes compliance with the requirements and restrictions listed in the informed consent
form (ICF) and in this protocol
At least 18 years of age at the time of signing the ICF
Diagnosed with gMG with confirmed documentation and supported by [CONTACT_2669] 1 of thefollowing:
DHistory of abnormal neuromuscular transmission demonstrated by [CONTACT_475912]
EHistory of positive edrophonium chloride test
FDemonstrated improvement in MG signs upon treatment with oralacetylcholinesterase (AChE) inhibitors as assessed by [CONTACT_1963]
Meeting the clinical criteria as defined by [CONTACT_475913]
(MGFA) class II, III, IVa, or IVb
Abdominal skin tissue allows for absorption and assessment of local safety of the planned
SC injection, as determined by [CONTACT_093]
An MG-$'/ WRWDO VFRUH RI  SRLQWV ZLWK PRUH WKDQ  RI WKH VFRUH GXHWRQRQRFXODU
symptoms at screening and baseline
Receiving a stable dose of other gMG treatment (concomitant gMG treatment) prior to
screening. For patients receiving nonsteroidal immunosuppressants (NSIDs), steroids,and/or AChE inhibitors as concomitant medications, the following dose conditions apply:
DNSIDs (eg, azathioprine, methotrexate, cyclosporine, tacrolimus, mycophenolate
mofetil, and cyclophosphamide): treatment initiated at least 6 months prior toscreening and no changes to dose in the 3 months before screening
ESteroids: treatment initiated at least 3 months prior to screening and no dose changes
in the month before screening
FAChE inhibitors: stable dose with no dose escalation during the [ADDRESS_610295], asrecommended by [CONTACT_475914]
Contraceptive use should be consistent with local regulations regarding the methods of
contraception for those participating in clinical studies and:
DMale participants are eligible to participate if they agree to the following during the
intervention period and for at least [ADDRESS_610296] study dose of the IMP:
Refrain from donating sperm
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 30  Plus either 
 Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a long term and persistent basis) and agree to  remain abstinent 
Or 
 Must agree to use a male condom with a female partner using an additionally 
highly effective contraceptiv e method with a failure rate of <1% per year as 
described in Section 10.5. when having sexual intercourse with a woman of 
childbearing potential who is  not currently pregnant 
Or 
 Be a sterilized man who has had a docu mented absence of sperm post-procedure 
b. Female participants are eligible to participate if they are not pregnant or 
breastfeeding, and they are 1 of the following: 
 Women of nonchildbearing potential (WONCBP), as defined in Section 10.5.1. 
Or 
 Women of childbearing potential (WOCBP) as defined in Section 10.5.1 and is 
using a contraceptive method that is highly effective (with a fa ilure rate of <1% 
per year) during the st udy intervention and for at l east [ADDRESS_610297] study 
dose of the IMP. The investigators should evaluate the potential for contraceptive 
method failure (eg, noncompliance) in rela tionship to the first dose of the study 
intervention 
 WOCBP must have a negative highly sensit ive serum pregnancy test within the 
screening period before the firs t dose of study IMP, see Section 8.2.8. 
 Additional requirements for pregnancy te sting during and after study intervention 
are located in Section 8.2.8. 
 The investigator is responsible for revi ew of medical histor y, menstrual history, 
and recent sexual activity to decrease the ri sk for inclusion of a woman with an 
early undetected pregnancy 
 
5.2. Exclusion Criteria  
Participants are excluded from the study if  any of the following criteria apply: 
1. Are pregnant or lactating, or intend to b ecome pregnant during the study or within [ADDRESS_610298] dose of IMP 
2. Has any of the following medical conditions: 
a. Clinically significant uncontrolled active or  chronic bacterial, viral, or fungal 
infection at screening 
b. Any other known autoimmune disease that, in the opi[INVESTIGATOR_871], would 
interfere with an accurate assessment of clinical symptoms of myasthenia gravis or 
put the participant at undue risk 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 31  c. History of malignancy unless  deemed cured by [CONTACT_475915]   years before the first administration of the IMP. Participants
with the following cancers can be included at any time:
adequately treated basal cell or squamous cell skin cancer
carcinoma in situ of the cervix
carcinoma in situ of the breast
incidental histological fi ndings of prostate cancer (TNM Classification of
Malignant Tumors stage T1a or T1b)
d. Clinical evidence of other significant serious diseases, or the participant has had a
recent major surgery, or who have any ot her condition that, in the opi[INVESTIGATOR_121523], could confound the results of  the study or put th e participant at undue
risk
Worsening muscle weakness secondary to concurrent infections or medications
(aminoglycosides, beta-blockers, etc.)
A documented lack of clinical response to plasma exchange (PLEX)
Received a live-attenuated vaccine fewer than 28 days before screening. Receiving aninactivated subunit, polysaccharide, or conjugate vaccine any time before screening is notexclusionary
Received a thymectomy <3 months prior to screening or 1 is planned to be performedduring the study period
The following results from these diagnostic assessments will be considered exclusionary:
DPositive serum test at screening for an active viral infection with any of the following
conditions:
Hepatitis B virus (HBV) that is indicative of an acute or chronic infection
(https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf, see
Section 10.8)
Hepatitis C virus (HCV) based on HCV antibody assay
Human immunodeficiency virus (HIV) based on a CD4 count of 200 cells/mm
[ADDRESS_610299] results that are associated with an acquired immunodeficiency syndrome
(AIDS)-defining condition, such as: Cyto megalovirus retinitis with loss of vision,
Pneumocystis jiroveci  pneumonia, chronic intestinal cryptosporidiosis, HIV-
related encephalopathy, Mycobacterium tuberculosis (pulmonary or
extrapulmonary), or invasive cervical cancer
EPositive nasopharyngeal swab test for SARS-CoV-2
Using the following prior or concomitant therapi[INVESTIGATOR_014]:
DUse of an investigational product within 3 months or 5 half-lives (whichever is
longer) before the first dose of IMP
EUse of any monoclonal antibody within [ADDRESS_610300] dose of the IMP
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 32  c. Use of Ig administered intrav enously (IVIg), SC (SCIg), or intramuscularly within 
4 weeks of screening 
d. Use of PLEX within 4 weeks of screening 
e. Previously participated in a clinical  study with efgartig imod and/or products 
coformulated with rHuPH20 and received at least 1 administration of IMP 
9. Total IgG levels <6 g/L at screening 
10. Current or history of (ie, within 12 months  of screening) alcoho l, drug, or medication 
abuse 
11. A known hypersensitivity reaction to efgartig imod, rHuPH20, or any of its excipi[INVESTIGATOR_840] 
5.3. Lifestyle Considerations 
5.3.1. Meals and Dietary Restrictions 
Participants will need to be fast ed for each visit. Fasted is defi ned as no food or drink except for 
water for at least 8 hours prior to the visit. Wat er is allowed until 4 hours prior to the visit. 
5.4. Screen Failures 
Screen failures are defined as participants who c onsent to participate in the clinical study but are 
not subsequently enrolled. Participants who fail to  meet the eligibility criteria will be considered 
screen failures. A minimal set of screen failure information is required to ensure transparent 
reporting of screen failure partic ipants to meet the Consolidated Standards of Reporting Trials 
(CONSORT) publishing requirements and to respond to queries from regula tory authorities. 
Minimal information includes demo graphy, screen failure details, eligibility criteria, and any 
serious adverse event (SAE). See the eCRF comple tion guidelines for a complete list of what 
will be collected for screen failures. 
Individuals who do not meet the criteria for participation in this study may be rescreened 
(ie, redoing the full assessments as per the Schedule of Activities (SoA) in Section 1.3. or 
retested once (ie, redoing assessments)  after sponsor’s written approval.  
Examples of conditions under wh ich rescreening may be consid ered include the following: 
x Individuals who required trea tment for an acute illness (eg, infection) may be 
rescreened once the illness is resolved  or the medical problem stabilized. 
Examples of conditions under wh ich retesting may be consid ered include the following: 
x Individuals who have clini cal laboratory tests value meeting 1 or more exclusion 
criteria which are not in line with the medi cal history and clinical evaluation of the 
individual, may be retested to confirm the valu e of the tests, if still allowed within the 
screening period. If not feasible, th e individual should be rescreened. 
Rescreened participants should be assi gned a new participant number for every 
screening/rescreening event. 
Clinical Study Protocol  ARGX-113-[ADDRESS_610301] be missed. See Section 7.1.  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 35  6.2.1. Preparation 
x Efgartigimod for IV administration will be  provided as a sterile, colorless, clear 
concentrate for solution for in fusion in glass vials. Appropriate dilutions in a 0.9% 
saline solution in an infusion ba g will be prepared at the si te prior to administration. 
x Efgartigimod for SC administration will be provided as a sterile, colorless to 
yellowish solution for inj ection in glass vials. 
x The IMP will be manufactured in accor dance with Good Manufacturing Practice 
regulations.  
6.2.2. Handling 
x The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all IMP received and any discrepancies are 
reported and resolved before use of the study intervention. 
x Only participants enrolled in the study ma y receive IMP and only authorized site staff 
may supply the IMP. IMP adminis tration must be performed by  [CONTACT_121947], in the SC 
treatment arm only, by [CONTACT_475916]. 
All IMP must be stored in a secure, e nvironmentally controlled, and monitored 
(manual or automated) area in  accordance with the labeled storage conditions with 
access limited to the investigator and authorized site staff. 
6.2.3. Storage 
x The IMP will be supplied to the pharmacy at the designated inve stigational site by 
[CONTACT_475917] r’s designated IMP supply vendor, who will 
also provide the investigator with the certifi cate of analysis, certificate of conformity, 
and European Union qualified person release documents. 
x The IMP must be stored refr igerated (2°C to 8°C or 35°F to 46°F) in its secondary 
packaging. It should not be exposed to fre ezing temperature or shaken, and it should 
be protected from direct sunlight during storage at the clinical site. 
x The investigator (or his/her de signee) is responsible for the correct and safe storage of 
the IMP assigned to the clinical site, in a locked, secure storage facility maintained 
within the appropriate temperature ranges, with access limited to  those individuals 
authorized to dispense the IMP. 
6.2.4. Accountability 
x The investigator, institution, or the head of the medical in stitution (where  applicable) 
is responsible for IMP accountability, reconciliation, and r ecord maintenance 
(ie, receipt, reconciliation, a nd final disposition records). 
6.3. Measures to Minimize Bias: Randomization and Blinding 
x This is an open-label study; potential se lection bias will be reduced by [CONTACT_385019]. 
Clinical Study Protocol  ARGX-113-[ADDRESS_610302] be 
administered by [CONTACT_475918], under medical supervision. After 
participants or caregivers are trained in  administration, the subsequent doses of 
efgartigimod PH20 SC may be administered by [CONTACT_475919] (see Section 6.2.2 ). All administrations in 
the IV treatment arm will be performed by [CONTACT_54113], under medical 
supervision. The date and tim e of each dose administered in the clinic will be 
recorded in the source documents. Th e dose of study intervention and study 
participant identification will be confirmed at the time of dosing by a member of the 
study-site staff other than the person administering the study  intervention.  
x The investigator should pr omote treatment compliance by [CONTACT_475920]’s safety and the valid ity of the study. The prescribed 
dose, timing, and mode of ad ministration cannot be changed.  All dates, start and end 
times of IMP administration, and any deviations from the intended regimen must be 
recorded in the eCRF. 
x A sponsor’s designated contract research organization (CRO) mon itor will review the 
pharmacy records at each site includi ng the drug accountability and dispensing 
records on which the pharmacist or designa ted person should record all IMP released 
for participant use. The sponsor’s designated CRO monitor will compare the dispensing record and vials with the individu al participant’s identifiers, kit number, 
and visit schedule to confirm that the part icipant received the co rrect treatment and 
dose, and that the dosing  schedule is correct. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 37  x Errors that are identified w ill be communicated to the site personnel to ensure that the 
errors are not repeated. The sponsor’s de signated CRO monitor’s report will include 
details of any missed doses, errors in dose, treatment or  scheduling errors, and the 
associated explanations. It wi ll be evaluated if these dosing errors will be reported as 
protocol deviations in the clinical database. All supplie s and pharmacy documentation 
must be made available throughout the study for the sponsor’s designated CRO 
monitor to review. 
6.4.1. Handling Missed Doses of the IMP 
All efforts will be made to ensure that the par ticipant receives all administrations of IMP on the 
scheduled day. If a participant misses any schedule d doses, he/she will not be discontinued from 
the study (see Section 7.1).  
6.4.2. Protocol Deviations 
The investigator should not implement any deviation from or  changes to the approved protocol 
without agreement of the sponsor and prior re view and documented appr oval of an amendment 
from the Institutional Review Board/Independent  Ethics Committee (IRB/IEC) and regulatory 
authority as per local regulation, except where ne cessary to eliminate an immediate hazard to 
study participants, or when the change involves only logistical or administrative aspects of the 
study (eg, change of telephone numbers). The in vestigator (or designe e) should document and 
explain a deviation from th e approved protocol.  
6.5. Dose Modification 
No dose modification is planned for this study. 
6.6. Continued Access to Study Interv ention After the End of the Study 
At the EoS visit on day 71±3, participants will be  offered the option to roll over into a single-
arm, open-label, extension study (ARGX-113-2002)  to receive efgar tigimod PH20 SC 1000 mg. 
Participants who complete the study may be eligible to partic ipate in the extension study.  
6.7. Treatment of Overdose 
For this study, any dose of efgartigimod IV or efgartigimod PH20 SC greater than 10% of the 
planned dosage amount (see Section 1.3) will be considered an overdose. There is no 
recommended specific treatment for an overdose of efgartigimod IV or efgartigimod PH20 SC. 
In case of suspected overdose, the participant sh ould be treated according to standard medical 
practice based on the investigator ’s judgment. The suspected ove rdose should be documented in 
the source documents and the e CRF, including any observed AEs. 
6.8. Concomitant Therapy 
Any medication or vaccine (including over-the-c ounter or prescription medicines, recreational 
drugs, vitamins, and/or herbal supp lements) that the participant is  receiving at the start of the 
study or receives during the study must be recorded in the eCRF along with: 
x Reason for use 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 38  x Dates of administration including start and end dates 
x Dosage information in cluding dose and frequency 
x Brand name (for vaccines only)   
The medical monitor should be contact[CONTACT_475921]. 
6.8.1. Prior Medication and Procedures 
Clinically relevant prior medication and procedures  received by [CONTACT_475922], including the start and stop dates of the therapy and if the therapy is ongoing. 
Clinically relevant prior medications and procedures includes: 
x Prior gMG medications and pr ocedures from 1 year prio r to screening, including the 
participant’s response to the therapy and the reason for changing the medication or 
dose 
x Prior non-gMG medication and procedures from 6 months prior to screening 
x All available vaccination history. When a vaccine requires multiple doses (eg, 
influenza vaccine) or a booste r, only the most recent v accination must be recorded 
6.8.2. Permitted Concomitant Medication and Procedures 
Participants are required to be  on a stable dose of concomitan t therapy for gMG. (inclusion 
criterion 7). Permitted concomitant therapy for gMG includes: 
x NSIDs (eg, azathioprine, methotrexate, cy closporine, tacrolimus, mycophenolate 
mofetil, and cyclophosphamide) 
x steroids 
x AChE inhibitors 
Administration of AChE inhibitors  must be withheld for at leas t 12 hours prior to performing the 
QMG assessment. Complying with this requirem ent will not be considered a change in the 
patient’s concomitant gMG treatment. 
Participants are allowed to receive vaccines that  do not use live or live-attenuated biological 
material. Any inactivated subunit, polysaccharid e, or conjugate vaccine is allowed at the 
discretion of the investigator and when administered at leas t [ADDRESS_610303] discontinue from the study interventi on if any prohibited therapi[INVESTIGATOR_103028]. 
During the study, participants may NOT receive: 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 39  x any monoclonal antibody 
x other experimental/study IMP 
x live or live-attenuated vaccines 
x a change in the dose or frequency of their current  gMG medication 
x a change in concomitant therapy for gMG 
x PLEX, IVIg, immunoadsorption, or a change in dosage or type of corticosteroid used 
as a monotherapy or in combination 
PLEX, Ig therapy (IVIg and SCIg), immunoadsor ption, or a change in dosage or type of 
corticosteroid are considered rescue therapy if both of the following conditions apply: 
1. The treating physician believes th at the participant’s health is in jeopardy if rescue 
therapy is not provided, and 
2. The participant is deteriorati ng clinically according to the pr otocol-defined criteria, which 
includes at least 1 of the following: 
a. new or worsening of respir atory/bulbar symptoms, or 
b. at least a 2-point increase in any indivi dual nonocular items on the MG-ADL scale as 
compared to the previous visit 
The date and time of rescue medication administration, as well as the name, dosage regimen, and 
response to the rescue medication will be recorded in the eCRF. 
Clinical Study Protocol  ARGX-113-[ADDRESS_610304] UDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL 
7.1. Discontinuation of Study Intervention 
Administration of the IMP may be withheld if, in  the opi[INVESTIGATOR_871], it could put the 
participant at undue risk. If the IMP is being withheld and it cannot be administered during the 
scheduled time window, then that dose of IMP must be missed. The subsequent scheduled dose 
of IMP can be administered to the participant at the next scheduled treatment period (TP) visit if 
the investigator determines that the undue risk has been resolved. The participant may continue with the study even if they miss multiple doses. 
It may be necessary for a participant to permanently discontinue study intervention.  
Participants must  discontinue the st udy intervention if: 
x It is in the participant’s best interest; disc ussion with the sponsor’ s medical director is 
encouraged prior to discontinuation 
x The participant receives pr ohibited medication (Section 6.8.3 ) 
x A severe hypersensitivity reaction to the IMP occurs 
x The participant is pregnant 
x The sponsor requests discontinuation (eg, following DSMB advice, see 
Section [IP_ADDRESS]) 
If study intervention is permanently  discontinued, the participant will remain in the study and 
will complete all scheduled vi sits and the EoS visit on day 71 (±3 days), even though the 
participant will not receive any more do ses of the IMP. See the SoA (Section 1.3) for data to be 
collected at the EoS visit. 
7.2. Participant Discontinuation/Withdrawal From the Study 
x Early discontinuation from the study is defined as the perm anent cessation of further 
participation in the study prior to its planned completion. 
x The reason for early discontinuation from the study will be clearly documented by [CONTACT_1275]. 
x A participant may withdraw from the study at any time at  his/her own request.  
x The participant will be permanently di scontinued both from the study intervention 
and from the study at that time. 
x Participants who discontinue from the study will not be repl aced. The sample size is 
inflated to account fo r attrition. See Section 9.2. 
x If the participant withdraws consent for disc losure of future information, the sponsor 
may retain and continue to use any data collected before such a withdrawal of 
consent. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 41  x If a participant withdraws from the study, he/she may re quest destruction of any 
samples taken and not tested, and the investig ator must document this request in the 
site study records and inform the sponsor as soon as possible. 
7.3. Lost to Follow-up 
A participant will be considered lost to follow- up if he/she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. 
The following actions must be taken if a participan t fails to return to the clinic for a required 
study visit: 
x The site must attempt to contact [CONTACT_475923]/or 
should continue in the study. 
x Before a participant is deemed lost to follow up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where  possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’ s last known mailing 
address or local equivalent methods). Thes e contact [CONTACT_14386] s hould be documented 
in the participant’s medical record. 
x Should the participant continue to be unreach able, he/she will be considered to have 
withdrawn from the study.  
x Site personnel, or an independe nt third party, will attempt to collect the vital status of 
the participant within legal and ethical boundaries for all participants randomized, 
including those who did not ge t study intervention. Public  sources may be searched 
for vital status information.  If vital status  is determined as deceased, this will be 
documented and the participant will not be  considered lost to follow-up. Sponsor 
personnel will not be involved in any attemp ts to collect vital status information. 
Discontinuation of specific sites or of the st udy as a whole are handled  as part of Section 10.1. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 42  8. STUDY ASSESSMENTS AND PROCEDURES 
x Study procedures and their timing ar e summarized in the SoA (Section 1.3). Protocol 
waivers or exemptions are not allowed. 
x Immediate safety concerns should be addr essed by [CONTACT_475924]. The investigator may decide wh ether to discontinue the IMP. If possible, 
the sponsor should be in volved in the decision. 
x Adherence to the study design requirements , including those specified in the SoA 
(Section 1.3), is essential and re quired for study conduct. 
x All screening evaluations must be comp leted and reviewed, and confirmed by [CONTACT_246221]/or the sponsor’s designated CRO to confirm that poten tial participants 
meet all eligibility criteria. The investigator  will maintain a screening log to record 
details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable. 
x At screening, all eligibility assessments should be performed after obtaining informed 
consent. 
x When a protocol-required procedure cannot  be performed, the investigator will 
document the reason, and any co rrective and preventative actions that he/she has 
taken to ensure that the protocol processe s are adhered to in the source documents. 
The study team should be informed of thes e incidents in a timely manner. These 
incidents will be considered a protocol de viation and will be recorded accordingly.  
8.1. Efficacy Assessments 
Planned time points for all efficacy assess ments are provided in the SoA (Section 1.3). 
8.1.1. Pharmacodynamics 
Total immunoglobulin G (IgG), IgG subtypes (I gG1, IgG2, IgG3, and IgG4) levels, and 
AChR-Ab levels will be measur ed using validated methods from  blood sampled as indicated in 
Section 1.3. AChR-Ab levels will only be measured in AChR-Ab seropositive participants. The 
actual date and time of the blood sample collection will be collect ed and included in the central 
laboratory data transfer. 
8.1.2. Clinical Efficacy Assessments 
The MG-ADL and the QMG assessments should  be administered by [CONTACT_475925] a given participant when possible. It is recomm ended to perform the 
MG-ADL scale prior to all other assessments. [IP_ADDRESS]. MG-ADL  
The MG-ADL is an 8-item patient-reported scale that assesses MG symptoms and their effects 
on daily activities. It evaluates a participant’s capacity to perform differe nt activities in their 
daily life, including talk ing, chewing, swallowing, breathing, br ushing their teeth, combing their 
hair, or getting up from a chair. The MG-ADL also  assesses double vision and eyelid droop. It is 
a discrete quantitative variable in which the 8 it ems are rated by [CONTACT_137382] a scale of 0 to 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 43  3. The total score can range from 0 to 24, with higher total scores  indicating more impairment. 
The MG-ADL assessment does not require any e quipment to perform. The scoring of the MG-
ADL should be performed by a trained and certified evaluator. 
[IP_ADDRESS]. QMG 
The QMG quantifies disease severity based on impairments of body functio n and structures as 
defined by [CONTACT_475926], Disa bility and Health. The QMG 
consists of 13 items that assess ocular, bulbar,  and limb function. Six of the 13 items are timed 
endurance tests measured in seconds. Each ite m has a possible score from 0 to 3. The total 
possible score is 39, where higher total scores indi cate more severe impair ments. It is based on 
qualitative testing of specific  muscle groups to assess limb function. The QMG requires minimal 
equipment, such as a spi[INVESTIGATOR_14007], mouthpi[INVESTIGATOR_475899], nose clips, a stopwatch, 
cups and water for the swallowing tests, a gonio meter, and a dynamometer. The scoring of the 
QMG should be performed by a trained evaluator and the scoring is based on the evaluator’s 
examination. 8.1.3. Myasthenia Gravis Quality of Life Qu estionnaire (15-item Scale Revised) 
The Myasthenia Gravis Quality of Life Question naire (15 item scale revised) (MG-QoL15r) is a 
15-item survey of a patient’s perceived health-r elated quality of life and addresses attributes 
known to be meaningful to a patient with gMG,  such as psychological well-being and social 
functioning. The patient assesses statements using a 3-point (0–2) Likert scale on the following 
domains: 
x mobility (9 items) 
x symptoms (3 items) 
x general contentment (1 item) 
x emotional well-being (2 items) 
Each item will be participant-scored using a 3-point severity scale ranging from 0 (not at all) to 2 
(very much), with a maximum pos sible score of 30. The MG-QoL15r  is helpful in determining 
the participant’s perception of the extent a nd dissatisfaction of MG-related dysfunction. 
8.1.4. EuroQoL 5 Dimensions 5 Levels 
The EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) is  a standardized measure of health status and 
was developed by [CONTACT_10616] a s imple, generic measure of  health status for 
clinical and economic apprai sal. The descriptive system  comprises 5 dimensions:  
x mobility 
x self-care 
x usual activities 
x pain/discomfort 
x anxiety/depression 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 44  Each dimension has 5 levels: 
x no problem 
x slight problem 
x moderate problem 
x severe problem 
x extreme problem 
The participant will be asked to indicate his/her health state by [CONTACT_13158] (or placing an “x” in) the 
box against the most appropriate st atement in each of the 5 dimens ions. This decision results in a 
1-digit number expressing the level selected for that d imension. The digits for 5 dimensions were 
combined in a 5-digit number describing the respondent’s health  state. A unique health state is 
defined by [CONTACT_106814] [ADDRESS_610305]. Each state is referred to in terms of a 5-digit code. For 
example, state [ZIP_CODE] would indicat e no problems in any of the 5 dimensions, while state [ZIP_CODE] 
would indicate no problem with mobility, slight problems with washing or dressing, moderate 
problems with doing usual activit ies, severe pain or discomfort, and extreme anxiety or 
depression.  
A visual analog scale is included in the questionnaire. Respondents are asked to mark the health 
status from 0 to 100 on the day the interview is conducted, with a score of 0 corresponding to 
“the worst health you can imagi ne” and 100 corresponding to “the best health you can imagine.” 
8.2. Safety Assessments 
Planned time points for all safety asse ssments are provided in the SoA (Section 1.3). 
8.2.1. Demographics 
Demographic characteristics comprise age, year of  birth, gender, race, an d ethnicity (per local 
regulations). Source data verification will be performed on race and ethnicity unless it is 
prohibited by [CONTACT_427]. 
8.2.2. Physical Examinations 
x A complete physical examination will in clude, at a minimum, assessments of the 
participant’s general appear ance, skin, lymph nodes, mu sculoskeletal/extremities, 
abdomen, cardiovascular, respi[INVESTIGATOR_13521] y, and neurological systems. 
x Height will be measur ed at screening only.  
x Weight will also be measured  at screening, baseline, a nd at the EoS visit. The 
participant is allowed to wear indoor daytime clothing with no shoes. 
x Investigators should pay special attention to clinical signs related to previous serious 
illnesses. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 45  8.2.3. Vital Signs 
x Vital signs (to be taken before blood collec tion for laboratory tests)  will be measured 
in a semi-supi[INVESTIGATOR_55848] [ADDRESS_610306] for the participant in a quiet setting without distra ctions (eg, television, cell 
phones). 
8.2.4. Electrocardiograms 
Single 12-lead ECG will be obtained after the par ticipant has rested in a supi[INVESTIGATOR_19636] 
5 minutes as outlined in the SoA (see Section 1.3) using an ECG machine that automatically 
calculates the heart rate and measures time be tween heart beats (RR), atrioventricular nodal 
delay (PR), duration of ventri cular depolarization (QRS), to tal duration of ventricular 
depolarization (QT), and rate-corrected QT inte rvals using Fridericia’s formula (QTcF). ECGs 
will be performed predose on dosing days. 
8.2.5. Medical and Surgical History 
Medical history will include: 
x All relevant medical histor y (eg, significant findings, surgeries and pre-existing 
conditions present at screening)  must be recorded in the eCRF regardless of whether 
it is related to gMG. 
x Previous emergency room (E R) visits, hospi[INVESTIGATOR_602], and intensive care unit (ICU) 
admissions from [ADDRESS_610307] of clinical laboratory tests to be performed and to the 
SoA (Section 1.3) for the timing and frequency. The details of sampling, handling, 
storage, and transportation of the samples wi ll be described in the laboratory manual. 
The actual sample collection date and time must be collected in the participant’s 
source document and included in the central laboratory data transfer. 
x The investigator must review the laboratory  report, document this  review, and record 
any clinically significant changes occurring during the study as an AE. The laboratory 
reports must be filed with the source documents.  
Clinical Study Protocol  ARGX-113-[ADDRESS_610308] be performed by [CONTACT_11378]. 
x Abnormal laboratory findings associated  with the underlying  disease are not 
considered clinically signifi cant unless judged by [CONTACT_475927]'s condition. 
x All laboratory tests with values considered  clinically significa ntly abnormal during 
participation in the study should be repeated until the values return to normal or 
baseline or are no longer considered clini cally significant by [CONTACT_373744]. 
 If any  values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_093], the etiol ogy should be identified, and the sponsor 
notified. 
 All protocol-required laboratory te sts, as defined in Section 10.2, must be 
conducted in accordance with the la boratory manual and the SoA (Section 1.3).  
 If laboratory values from nonprotocol specified laborator y tests performed at the 
institution’s local laboratory require a ch ange in participant management or are 
considered clinically sign ificant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the outc omes must be recorded. 
[IP_ADDRESS]. Hematology, Clinical Chemistry, and Urinalysis 
Blood and urine samples for clinical safety labo ratory assessments, in cluding hematology, blood 
chemistry, and urinalysis, will be collected at  the timepoints specified in the SoA (Section 1.3). 
The list of clinical safety laboratory parameters for hematology, clinical chemistry, and 
urinalysis are provided in Table 3 . 
x Blood samples for clinical laboratory assess ments will be taken while the participant 
is in the fasted condition, defined as no food or drink (e xcept for wate r) for 8 hours. 
Water is permitted up to 4 hour s prior to th e assessment. 
x Blood samples for safety assessments will be collected according to the laboratory 
manual. 
x The samples will be analyzed at the central laboratory. 
x Clinical laboratory tests w ill be reviewed for potential cl inically significant findings 
at all time points throughout the study. Findings meeting the definition of an AE (see 
Section 10.4) must be recorded on an AE page of the eCRF. See Section 10.4.3 for 
information on following up of clin ically significant abnormalities. 
x Laboratory tests with values considered c linically significantly abnormal during the 
study that meet the definition o f
 an AE w ill be monitored until the values return to 
normal or baseline or are no longer consid ered clinically si gnificant by [CONTACT_63200]. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 47  [IP_ADDRESS]. Virus Serology 
For exclusion criterion 7.a, blood will be sampled and evaluate d for virus serology as described 
in Section 10.2.  
[IP_ADDRESS]. Follicle-Stimulating Hormone Level 
Female participants must have their follicle-s timulating hormone (FSH) level measured at the 
time points listed in the SoA (Section 1.3)  as described in Section 10.2. 
[IP_ADDRESS]. SARS-CoV-[ADDRESS_610309] 
Nasal and throat mucosal cell samp les will be collected according to the laboratory manual at the 
time points specified in the SoA (Section 1.3) to be tested for SARS-CoV-2. 
8.2.7. Assessment of Administration Site 
The injection site of participants receiving ef gartigimod PH20 SC will be continuously assessed 
by [CONTACT_2299] (see Section 1.3). On dosing days, the assessment will be performed by [CONTACT_475928] [ADDRESS_610310] received 
efgartigimod the assessment will include asking the participants about any injection site reactions 
that occurred between visits. Any injection site re action will be reported as an AE (Section 8.3). 
8.2.8. Pregnancy Testing 
x Refer to inclusion criteria 8.b for pregnancy testing entry criteria. 
x Pregnancy testing at screen ing will be a highly sens itive serum test, and all 
subsequent pregnancy testing will be done using urine tests.  Pregnancy testing should 
be conducted as indicated in the SoA (Section 1.3) during the study. If local 
regulations require more frequent or sensit ive testing, then the local regulations will 
be followed. 
x Pregnancy testing (urine or serum as required by [CONTACT_427]) should be 
conducted at the end of relevant systemic exposure. 
x Additional serum or urine pregnancy te sts may be performed, as determined 
necessary by [CONTACT_11006], to establish the absence 
of pregnancy at any time during the subject's participat ion in the study. 
8.2.9. Immunogenicity 
[IP_ADDRESS]. ADA Against Efgartigimod 
Blood samples will be collected to assess the serum levels of ADA against efgartigimod as 
indicated in the SoA (Section 1.3). Sampling will be done predose on IMP administration visits. 
As per regulations, all samples wi ll be analyzed in a 3-tiered approach using validated methods8: 
1. First, all samples will be evaluated in a screening assay (tier 1) and scored as ADA 
positive or negative. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 48  2. Samples that screen positive in  tier 1 will be evaluated in the confirmatory ADA assay to 
assess the specificity of the ADA response. The samples will be scored as either 
confirmed positive (ie, positive immunodeplet ion) or confirmed negative (ie, negative 
immunodepletion). 
3. Samples confirmed to be positiv e for ADA in tier 2 will be furt her analyzed in a titration 
assay to characterize the magnitude of the ADA response and a neutralizing antibody 
(NAb) assay to assess the ADA for neutralizing activity. 
If no sample was taken, the reason will be recorded. 
[IP_ADDRESS]. ADA Against rHuPH20 
Blood samples will be collected to assess the plasma levels of ADA against rHuPH20 as 
indicated in the SoA (Section 1.3). Sampling will be done predose on IMP administration visits. 
As per regulations, all samples wi ll be analyzed in a 3-tiered approach using validated methods8: 
1. First, all samples will be analyzed in a scre ening assay (tier 1), which identifies putative 
positive or negative samples. 
2. Samples that screen positive in  tier 1 will be evaluated in the confirmatory ADA assay to 
assess the specificity of the ADA response. The samples will be scored as either 
confirmed positive or negative. 
3. Samples confirmed to be positiv e for ADA in tier 2 will be furt her analyzed in a titration 
assay to characterize the magnitude of the ADA response an d a neutralizing antibody 
(NAb) assay to assess the ADA for neutralizing activity. 
If no sample was taken, the reason will be record ed in the relevant section of the eCRF. 
8.2.10. Suicidal Ideation and Behavior Risk Monitoring 
x Efgartigimod is being developed for a neur ologic indication, so suicidal ideation and 
risk behavior monitori ng (SIB) is required. 
x Participants being treated with efgartigim od should be monitore d appropriately and 
observed closely for suicidal ideation and behavior or any other unusual changes in 
behavior, especially at the beginning and e nd of the course of intervention, or at the 
time of dose changes, either increases or decreases. 
x Participants who experience signs of suic idal ideation or beha vior, should undergo a 
risk assessment. All factor s contributing to suicidal ideation and behavior (SIB) 
should be evaluated and consideration should be given to discontinuation of the study 
intervention. 
x Baseline assessment of suicidal ideation and behavior and intervention emergent 
suicidal ideation and behavi or will be monitored by [CONTACT_475929] (PHQ) item 9: "Over the last [ADDRESS_610311]?" 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 49  8.3. Adverse Events (AEs), Serious Ad verse Events (SAEs), and Other 
Safety Reporting 
x The definitions of AEs and SAEs can be found in Section 10.4. 
x AEs will be reported by [CONTACT_2299] (o r, when appropriate, by a caregiver, 
surrogate, or the participant's lega lly authorized representative). 
x The investigator and any qualified desi gnees are responsible for detecting, 
documenting, and recording events that me et the definition of an AE or SAE and 
remain responsible for following up AEs that  are serious, considered related to the 
study intervention or study procedures, or th at caused the participant to discontinue 
the study intervention (see Section 7). 
x An unexpected AE is any adverse drug event, which is not listed in the reference 
safety information in the current IB or is not  listed at the specificity or intensity that 
has been observed in the current study. 
x Suspected adverse drug reaction means a ny AE for which there is a reasonable 
possibility that th e IMP caused the AE. 
x Each AE is to be evaluated for dura tion, severity (using the Common Terminology 
Criteria for Adverse Events [CTCAE] criter ia version 5.0), seriousness, and causal 
relationship to the IMP or st udy procedures. The action taken with the investigational 
drug and the outcome of the event must also be recorded. 
x The method of recording, evaluating, and assessing causality of AEs and SAEs and 
the procedures for completing and tran smitting SAE reports are provided in 
Section 10.4. 
8.3.1. Time Period and Frequency for Co llecting AE and SAE Information 
x All AEs and SAEs will be collected from th e signing of the ICF until the EoS visit at 
the time points specified in the SoA (Section 1.3). 
x All SAEs will be recorded and reported to  the sponsor or designee immediately and 
under no circumstance should this exceed 24 hours from awareness of the site staff, as indicated in Section 10.4. The investigator will submit  any updated SAE data to the 
sponsor within 24 hours of it being available. 
x Investigators are not obligate d to actively seek informa tion on AEs or SAEs after 
conclusion of the study participation. However, if the investigator learns of any SAE, 
including a death, at any time after a participant has been  discharged from the study, 
and he/she considers the event to be reasonably related to the study intervention or study participation, the investigator must promptly notify the sponsor. 
8.3.2. Method of Detecting AEs and SAEs 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
nonleading verbal questioning of the participant is the prefer red method to inquire about 
AE occurrences. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 50  8.3.3. Follow-up of AEs and SAEs 
After the initial AE/SAE report, th e investigator is required to pr oactively follow each participant 
at subsequent visits/contacts. All SAEs and AE s of special interest (AESI) as defined in 
Section 8.3.[ADDRESS_610312] to follow-up (as defined in Section 7.3). Further information on follow-up 
procedures is provided in Section 10.4.3. 
8.3.4. Regulatory Reporting Requirements for SAEs 
x Prompt notification by [CONTACT_475930] a study intervention under clinical investig ation are met. 
x The sponsor has a legal responsibility to not ify both the local re gulatory authority and 
other regulatory agencies about the safety  of a study intervention under clinical 
investigation. The sponsor will comply with  country-specific regulatory requirements 
relating to safety reporting to the regulato ry authority, IRB/IEC, and investigators. 
x An investigator who receives an investigator safety repor t describing an SAE or other 
specific safety information (eg, summary or  listing of SAEs) from the sponsor will 
review and then file it along with the IB and will notify the IRB/IEC, if appropriate 
according to local requirements. 
x The sponsor (or its designee) will be res ponsible for reporting suspected unexpected 
serious adverse reactions (SUS ARs) to the relevant regu latory authorities and the 
IEC/IRB as per applicable re gulatory requirements. The sp onsor (or its designee) will 
also be responsible to forw ard S[LOCATION_003]R reports to all i nvestigators involved in the 
study, who will also be required to repor t these S[LOCATION_003]Rs to their respective 
IECs/IRBs, as per their local regulatory requirements. 
8.3.5. Pregnancy 
x Details of all pregnancies in female participants will be collected after the start of 
study intervention and until [ADDRESS_610313] pregnancy information on the 
appropriate form and submit it to the spons or within 24 hours of learning of the 
female participant or female partner of ma le participant (after obtaining the necessary 
signed informed consent from the female partner) pregnancy. 
x While pregnancy itself is not considered  to be an AE or SAE, any pregnancy 
complication or electiv e
 termination of a pregnancy for medical reasons will be 
reported as an AE or SAE. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 51  x Abnormal pregnancy outcomes (eg, spontan eous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs and will be reported 
as such. 
x The pregnant participant will be followed to  determine the outcome of the pregnancy. 
The investigator will collect follow-up information on the participant and the neonate 
and the information will be forwarded to the sponsor. 
x If a female partner of a male participant c onsents, the female part ner will be followed 
to determine the outcome of the pregnancy. In this case, the investigator will collect follow-up information on the female partne r and the neonate and the information will 
be forwarded to the sponsor. 
x Any post-study pregnancy-related SAE consid ered reasonably related to the study 
intervention by [CONTACT_475931] 8.3.4. While the investigator is not obligated  to actively seek this information 
in former study participants or pregnant  female partners of  former male study 
participants, he/she may learn of an SAE through spontaneous reporting. 
x Any female participant who becomes pregnant while particip ating in the study will be 
discontinued from the study intervention and will continue with all remaining visits, 
including the EoS visit. 
8.3.6. Adverse Events of Special Interest 
An AESI is an event of scientific and medica l concern specific to th e sponsor’s product or 
program (eg, an underlying condi tion being investigated, a me chanism of action/potential 
immunosuppression). An AESI can be serious or nonserious and related or unrelated to study 
IMP or procedures. Further characterizing in formation will be collected in the eCRF.  
Efgartigimod treatment induces reductions in the IgG levels and there is a potential risk for infections associated with low IgG levels. As such, any infections are co nsidered AESIs in this 
study. Further information to be co llected in the eCRF will include: 
x Location of the infection 
x Relationship to the underlying conditi on, medical history, and concomitant 
medications 
x Reoccurrence of previous infection 
x Previous rescue therapy 
x Any confirmatory procedure, culture , or urgent medical intervention 
8.4. Pharmacokinetics 
x Blood samples for pharmacokine tics (PK) will be collected  from each participant as 
specified in the SoA (Section 1.3). Concentrations of efgartigimod will be determined 
using a validated method. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 52  x Instructions for the collection and handling of biological samples will be provided by 
[CONTACT_456]. The actual date and time (24-hour clock time) of each sample will be 
recorded. 
x Samples collected for analyses of efgartig imod concentration may also be used to 
evaluate safety or efficacy aspects relate d to concerns arising during or after the 
study. 
x At visits during which blood samples for the determination of mu ltiple aspects of 
efgartigimod will be taken, 1 sample of sufficient volume can be used. 
x For the efgartigimod IV treatment arm, PK sampling will be performed both predose 
(within 1 hour prior to the start of the in fusion) and postdose (w ithin 1 hour after the 
end of the infusion) on dosing days. For th e efgartigimod PH20 SC treatment arm, PK 
sampling will only be done predose (within 1 hour prior to the injection) on dosing 
days. 
x The following PK parameters will be measured: C max of efgartigimod (after all doses 
for the IV treatment arm) and C trough of efgartigimod in both arms.   
8.5. Genetics and/or Pharmacogenomics 
Genetics are not evaluated in this study. 
8.6. Biomarkers 
See Section 8.1.[ADDRESS_610314] been 
completed may be stored for up to 15 years after the end of the study for additional medical, 
academic, or scientific research to address any sc ientific questions related to efgartigimod, FcRn 
biology, or gMG. The samples may be stored in the laboratory or long-term storage designated 
by [CONTACT_475932]. The storage and future use of samples obtained 
during this study is permitted unless local regulati ons do not allow it or if the participant did not 
consent.  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 53  In addition, blood samples may be used to validate methods to measure ef gartigimod, antibodies, 
and biomarkers. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 54  9. STATISTICAL CONSIDERATIONS 
The statistical analysis will be performed by [CONTACT_456]’s designated CRO using statistical 
analysis systems (SAS) software (SAS Institute, Cary, NC, [LOCATION_002] ) version 9.[ADDRESS_610315] operating proced ures (SOPs) and work 
instructions of the sponsor’s designated CRO w ill be used as the default methodology if not 
otherwise specified.  
A detailed and comprehensive Statistical Analys is Plan (SAP) will be written and signed-off 
prior to final analysis database lock. Minor chan ges to the statistical methods set out in this 
protocol do not require a protocol amendment but will be documented (as changes from the 
protocol) in the SAP and in the clinical study report(s). The be low sections contain the main 
general features of the statis tical analysis. More details wi ll be provided in the SAP. 
9.1. Statistical Hypotheses 
The confirmation of the noninferiority (NI) of efgartigimod PH20 SC with efgartigimod IV will 
be based on the total IgG percent reduction at da y 29 utilizing a noninferio rity margin of 10. See 
Section 9.2 for justification of the no ninferiority margin. The hypot heses for the evaluation of 
noninferiority are as follows: 
x Null hypothesis: the difference in percent reduction from baseline of total IgG at 
day  IRU WKH 6& WUHDWPHQW DUP DV FR PSDUHGWRWKH,9WUHDWPHQWDUP ZLOO EH 
(ie, ȝIV - ȝSC   
x Alternate hypothesis: the difference in per cent reduction from baseline of total IgG at 
day 29 for the SC treatment arm as compared to the IV treatment arm will be <10 
(ie, ȝIV - ȝSC <10) 
9.2. Sample Size Determination 
The noninferiority (NI) evaluati on will be based on the percent reduction from baseline in total 
IgG levels at day 29. 
To evaluate the relationship between changes in  total IgG and MG-ADL, statistical modeling on 
MG-ADL change from study baseli ne with total IgG percent re duction from study baseline as a 
predictor and participant as a random effe ct was performed among all study ARGX-113-1704 
participants on the efgartigimod IV 10 mg/kg trea tment arm in the modified intention-to-treat 
(mITT) analysis set. Data fro m all cycles in the study were included. To mini mize potential 
modeling bias introduced by [CONTACT_475933], only week 1 to week 6 data were included and 
data after week 6 were excluded. The modeling resu lts demonstrate that total IgG percent change 
from study baseline and MG-ADL change from study baseline were highly correlated 
(p-value <0.0001) as illustrated in  Figure 2 . With a difference  of 10 in the mean total IgG percent 
reduction (eg, from total IgG percent reduction of 63 to total IgG percent reduction of 53) the 
mean difference in MG-ADL impr ovement (ie, decrease from ba seline) is expected to be 0.35 
(2-sided 95% confidence interval, 0.236 to 0.465). In the phase 3 study ARGX-113-1704, the 
mean of MG-ADL improvement at week 4 of  cycle 1 was 4.5 (standard error 0.36) in the 
efgartigimod treatment gr oup and 2.0 (standard error 0.27) in the placebo treatment arm, which 
translates to a treatment effe ct of 2.5 (2-sided 95 % confidence interval, 1.62 to 3.38). The 
corresponding mean of total IgG percent reduction at week 4 of cycle 1 was 62.2 (standard error 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 55  0.82) in the efgartigimod treatment arm and 0.1 (standard error 2.23) in  the placebo treatment 
arm, which translates to a trea tment effect of 62.1 (2-sided  95% confidence interval, 57.44 to 
66.76). With a NI margin of 10 in IgG percent reduction, 84 % (1–10/62.2 x 100%) of the PD 
effect as assessed by [CONTACT_475934], whereas 86% (1–0.35/2.5 x 
100%) of the clinical effect as assessed by [CONTACT_4224] -ADL change is expected to be preserved. 
Figure 2: Statistical Modeling on MG-ADL Change From Baseline With IgG Percent 
Reduction From Baseline as a Predicto r and Patient as a Random Effect in 
All Efgartigimod IV Treated Patients in Study ARGX-113-1704 (mITT 
Analysis Set) 
 
IgG= immunoglobulin G; IV=intravenous(ly); MG-ADL=Myasthenia Gravis Activities of Daily Living; 
mITT=modified intention-to-treat 
Note: To minimize potential modeling bias introduced by [CONTACT_475933], only week 1 to week 6 data from all 
cycles in study ARGX- 113-1704 were included. 
 
Based on data from the phase 3 study ARGX-113-1704, the mean pe rcent decrease in total IgG 
levels with the IV formulation is expected to be approximately 62 (standard deviation 7.5). 
Assuming the total IgG percent reduction from ba seline with the SC formulation is 60 (2 less 
compared to the IV formulati on) along with a standard devi ation of 7.5, 20 participants per 
treatment arm are needed to reach 90% power to detect noninferiority usi ng a 1-sided 2-sample t-
test at a 2.5% level of significance. To account for particip ant discontinuation, [ADDRESS_610316]  been added. A sample size of 46  participants will need to be 
enrolled and randomized, allowi ng for a 13% attrition rate. 

Clinical Study Protocol  ARGX-113-[ADDRESS_610317] deviation is:  
x 8.5, then a total of 50 participants will be recruited, with 6 additional participants 
added to account for discontinuations for a total of 56 participan ts (based on a pooled 
standard deviation of 8.5) 
x 10.0, then a total of 68 particip ants will be recruited, with  8 additional participants 
added to account for discontinuations for a total of 76 participan ts (based on a pooled 
standard deviation of 10) 
Seventy-six participants would suffice for the noninferiority comparison between SC and IV 
based on IgG reduction at day 29; however, increasing the sample size to approximately 110 
participants will provide better quantification of the clinical safety and efficacy profile of the SC 
formulation in patients with gMG while the IV fo rmulation will serve as a reference treatment in 
this randomized study. 
Note : “Enrolled” means a participant's, or their le gally acceptable representative’s, agreement to 
participate in a clinical study following comp letion of the informed  consent process and 
screening. Potential participants who are screen ed to determine eligibil ity for the study, but do 
not participate in the study, ar e not considered enrolled unl ess otherwise specified by [CONTACT_12695]. “Randomized” means that an enrolled  participant has been randomly assigned to a 
treatment arm. 
9.3. Analysis Sets 
The following analysis sets are defined: Table 2: Analysis Sets 
Analysis Sets Description 
Safety analysis set  All randomized participants who are exposed to 
the IMP  
Intention-to-treat set  All randomized  participants with a value for total 
IgG levels at baseline and at least [ADDRESS_610318] 
administration of efgartigimod. 
x All study visits will be recalculated based on actual dates and will be referred to as 
“analysis visits,” which will be used in  the statistical analyses. The rules for 
calculating the analysis visi ts will be documented in the SAP. Rules for inputting 
partial dates or missing dates will also be documented in the SAP. 
9.4.2. Primary Endpoint 
Definition of the Estimand for the Primary Endpoint 
x Population: intention-to-tre at (ITT) analysis set (see Table 2 ) 
x Variable: Percent reduction from baseline in total IgG levels at day 29 
x Main intercurrent events: 
 early treatment discontinuation fo r any reason prior to day 29 
 initiation of Ig therapy (IVIg and SCIg ) as rescue therapy prior to day 29 
 missed doses 
Handling of Main Intercurrent Events 
For early treatment discontinuati on or missed doses, the observation captured [ADDRESS_610319] and Statistical Inference 
An analysis of covariance model (ANCOVA) will be used to estimate the mean percent 
reduction in total IgG levels from baseline at da y 29 for each treatment arm, as well as the 
2-sided 95% confidence interval for the differen ce between the 2 treatment arms. The model will 
include treatment as a factor and baseline total IgG level as a covariate. 
When the upper limit of the 95% confidence interval (mean per cent reduction with IV – mean 
percent reduction with SC) is below the margin  of 10, the SC formulation will be considered 
noninferior to the IV formulation. 
Complementary Analyses 
To facilitate interpretation of th e estimated treatment effect in the primary analysis, sensitivity 
analyses will be conducted where the main inte rcurrent events will be  handled differently. 
Details will be provided in the SAP. 
Clinical Study Protocol  ARGX-113-[ADDRESS_610320] deviat ion, 95% 2-sided confidence interval, 
median, first quartile (Q1), third qua rtile (Q3), minimum, and maximum. 
In addition, the differenc e in the percentage of MG-ADL responders between the 2 treatment 
arms will be analyzed using the meta-analysis predictive approach while incorporating the 
treatment cycle 1 data from the efgartigim od IV treatment arm in  study ARGX-113-1704 as 
historical active controls.7  
9.4.4. Exploratory Endpoints 
Exploratory endpoints will be summarized with descriptive statistics by [CONTACT_475935]. 
9.5. Interim Analysis 
Interim analyses may be performed to support questions from authorities  and/or submissions. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 59  10. SUPPORTING DOCUMENTAT ION AND OPERATIONAL 
CONSIDERATIONS 
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations 
10.1.1. Regulatory and Ethical Considerations 
This study will be conducted in accordance w ith the protocol and with the following: 
x Consensus ethical principles derived fro m international guide lines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines 
x Applicable International Council for Harmonisation (ICH)  Good Clinical Practice 
(GCP) Guidelines 
x Applicable laws and regulations 
The protocol, protocol amendmen ts, ICF, IB, and other relevant  documents (eg, advertisements) 
must be submitted to an Institutional Review  Board/Independent Ethics Committee (IRB/IEC) 
by [CONTACT_22843]/IEC before the study is initiated. 
x Any amendments to the pr otocol will require I RB/IEC approval before 
implementation of changes made to the st udy design, except for changes necessary to 
eliminate an immediate hazar d to study participants.  
x Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation excep t for changes necessary  to eliminate an 
immediate hazard to study participants. 
The investigator will be res ponsible for the following: 
x Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC 
x Notifying the IRB/IEC of SAEs or other sign ificant safety findings as required by 
[CONTACT_1744]/IEC procedures 
x Providing oversight of the conduct of th e study at the site and adherence to 
requirements of 21 Code of Federal Regulatio ns (CFR), ICH guideli nes, the IRB/IEC, 
European regulation 536/2014 for clinical studies, and all other applicable local 
regulations 
10.1.2. Financial Disclosure 
The sponsor will fund the study as outlined in the clinical study agreement. 
The sponsor will obtain adequate global/local in surance for the study participants including the 
study participants for the required duration of time. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 60  The sponsor maintains an insurance coverage fo r this study in accordance with the laws and 
regulations of the countries in  which the study is performed. Li ability and insu rance provisions 
for this study are specified in the investigator’s  contract. The terms and conditions will apply as 
specified in the policy document. 
Investigators and sub-investigators will provide th e sponsor with sufficie nt accurate financial 
information as requested to allow the sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appr opriate regulatory author ities. Investigator are 
responsible for providing information on financial interests du ring the course of the study and for 
1 year after comple tion of the study. 
10.1.3. Informed Consent Process 
x Prior to signing the ICF, the study participants will be instru cted not to participate in 
any other clinical study that involves a th erapeutic intervention until the completion 
of the study. 
x Any participant that provides informed c onsent will be assigned a unique participant 
ID via the Intera ctive Response Technology (IRT) system. 
x The investigator or his/her representative will explain to the participant all of the 
following: the nature of the study, its purpos e, the procedures i nvolved, the expected 
duration, any potential discomfort, potential alternative procedure(s) or course(s) of 
treatment available, and the extent of maintain the confidentiality of the participant’s 
records. The investigator or his/her repres entative will answer all questions from the 
participant regarding the study. 
x Participants must be informed that their participation is voluntary, that they may withdraw from the study at any time, and th at withdrawal of c onsent will not affect 
their subsequent medical treatment or relationship with the treating physician. 
x Participants  will be required to sign a statement of informed consent, after receipt of 
detailed information on the study, that me ets the requirements of [ADDRESS_610321] 
(HIPAA) requirements, where applicable, and the IRB/IEC or study center. 
x The ICF will be used to explain the potential risks and benefits of study participation 
to the participant in simple terms before the participant is screened. 
x The medical record must include a statem ent that written informed consent was 
obtained before the participant was enroll ed in the study and the date the written 
consent was obtained. The authorized pers on obtaining the informed consent must 
also sign the ICF. 
x A separate ICF will be issued in case of pregnancy of a female partner of a male participant. If required by [CONTACT_427] , a separate pregnancy ICF will be issued 
for female participants who become pregnant.  
x All participant information and ICFs must be availab l
 e in the local and vernacular 
languages required at the site and include participant in formation sheets/brochures 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 61  that outline the study procedures. All IC F(s) must be signed and dated by [CONTACT_2416]. 
x Participants must reconsent to the most current version of the ICF(s) during their 
participation in the study. 
x The investigator is responsi ble for ensuring that informed consent is obtained from 
each participant and for obtaining the appr opriate signatures and dates on the ICF 
prior to the performance of any protocol proc edures and prior to the administration of 
the IMP. 
x A copy of the signed and dated ICF(s) mu st be provided to the participant. 
x A participant who is rescreened or retested is not required to si gn another ICF if the 
rescreening occurs within  the screening period. 
10.1.4. Data Protection 
x Participants will be assigned a unique id entifier by [CONTACT_456]. Any participant 
records or datasets that are transferred to  the sponsor will contain the identifier only; 
participant names or any information which would make the participant identifiable 
will not be transferred. 
x The participant must be informed that his/her personal study-related data will be used 
by [CONTACT_475936] w ith local data protection law.  The level of disclosure 
must also be explained to the participant who will be required to give consent for their data to be used as descri bed in the informed consent.  
x The participant must be informed that hi s/her medical records may be examined by 
[CONTACT_475937], by [CONTACT_6667]/IEC member s, and by [CONTACT_9326]. 
10.1.5. Committees Structure 
[IP_ADDRESS]. Data Safety Monitoring Board 
x Participant safety will be monitored by [CONTACT_45959], which includes safety signal detection at any time during the study. 
x The DSMB will consist of an independent  group of clinical experts who are not 
involved in the study management. The objectiv e of the DSMB will be to review and 
evaluate all available safety data. The pla nning and frequency of th e meetings will be 
detailed in the DSMB charter. Additionally, ad hoc meetings can be requested at any 
time during the study by [CONTACT_475938].  
x The DSMB will advise the sponsor regard ing continuation, modification, temporary 
discontinuation, or termination of  the study after every meeting. 
x The composition, objectives, role, and respons ibilities of the DSMB will be described 
in the DSMB charter, which will be ag reed to by [CONTACT_475939]-113-[ADDRESS_610322] or verify 
documents to verify participant’s chart and eCRF records. Such information must be 
kept confidential in locked facilities that allow for this. The investigator will prepare 
and maintain adequate and accurate source documents to record all observations and 
other pertinent data for each par ticipant screened for the study. 
x The investigator is responsible for mainta ining source documents. These will be made 
available for verification by [CONTACT_78265] r’s designated CRO monitor at each 
monitoring visit. The inves tigator must submit an eCRF  for each participant, 
regardless of duration of partic ipation or administration of IM P (ie, an eCRF has to be 
submitted for screen failures as well). All supporti ve documentation submitted with 
the eCRF, such as laboratory or hospi[INVESTIGATOR_93476], should be clearly identified with the 
study and participant number. Any personal information, including participant name, 
should be removed or rendered ille gible to preserve data privacy. 
10.1.7. Data Quality Assurance 
x All participant data relating to the study w ill be recorded on printed or electronic CRF 
unless transmitted to the spons or or designee electronically  (eg, laboratory data). The 
investigator is responsible fo r verifying that da ta entries are accurate and correct by 
[CONTACT_113559]. 
x The investigator must maintain accurate documentation (source data) that supports 
the information entered in the eCRF if  and where applicable. No source data 
verification will be performed on race and ethnicity only if requested per local 
regulations. 
x Guidance on completion of eCRFs will be provided in the eCRF completion 
guidelines by [CONTACT_1701].  
x The investigator must perm it study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents. 
x Monitoring details describing strategy (eg, risk-based initiatives in operations and 
quality such as Risk Management and M itigation Strategies and Analytical Risk-
Based Monitoring), methods, re sponsibilities and requireme nts, including handling of 
noncompliance issues and monitoring tec hniques (central, remote, or on-site 
monitoring) are pr ovided in the monitoring plan. 
x The sponsor or designee is responsible for the data ma nagement of this study, 
including quality ch ecking of the data. 
x The sponsor assumes accountability for ac tions delegated to other individuals 
(eg, CROs). 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 63  x Study monitors will perform ongoing source da ta verification to confirm that data 
entered into the eCRF by [CONTACT_113640] s ite personnel are accurate, complete, and 
verifiable from source documents; that the sa fety and rights of pa rticipants are being 
protected; and that the st udy is being conducted in accord ance with the currently 
approved protocol and any other study ag reements, ICH GCP, and all applicable 
regulatory requirements.  
[IP_ADDRESS]. Data Handling and Record Keepi[INVESTIGATOR_201999]’s res ponsibility to maintain essentia l study documents  (records and 
documents pertaining to the conduct of this study and the distribution of IMP, including 
regulatory documents, eCRFs, signed participan t ICFs, laboratory test results, IMP inventory 
records, source documents, relevant correspond ence, AE reports, and all other supporting 
documentation) as required by [CONTACT_3433] e applicable national regulatory requirements. The study site 
should plan on retaining such doc uments for approximately [ADDRESS_610323] 2 ye ars after the formal disc ontinuation of clinical 
development of the IMP. The sponsor will notify the principal investigator [INVESTIGATOR_54070].  
These documents should be retained for a longer  period if required by [CONTACT_3433] e applicable regulatory 
requirements or the hospi[INVESTIGATOR_307], institution, or private practice in which the study is being 
conducted. Participant identification codes (par ticipant names and corresponding study numbers) 
will be retained for this same period of time. These documents may be transferred to another 
responsible party, acceptable to the sponsor, who agrees to abide by [CONTACT_44148]. The 
investigator is required to notif y the sponsor (or an authorized re presentative) in writing prior to 
changing the location or status of  any essential clinical study documents. Th e investigator must 
contact [CONTACT_475940]. 
No records may be destroyed during the retent ion period without the written approval of the 
sponsor. No records may be transf erred to another location or pa rty without written notification 
to the sponsor. 
For studies conducted outside the US under an US  investigational new drug (IND), the principal 
investigator [INVESTIGATOR_350110]. 
[IP_ADDRESS]. Quality Assurance Audit 
Study processes, study sites (incl uding, but not limited to site visits, central laboratories, 
vendors), the study database, and study documentation may be subjec t to quality as surance audit 
during the course of the study by [CONTACT_4209]’s designee (CRO or other vendor) on 
behalf of sponsor. In addition, inspections may be conducted by [CONTACT_386618]. Such audits/inspections can occur at any time during or after completion of the study. 
[IP_ADDRESS]. Quality Control 
Quality cont rol will be applied to 
each stage of study-related activities. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 64  The following steps will be taken to ensure the accuracy, consistency, completeness, and 
reliability of the data: 
x Investigator meetings 
x Central laboratories for clin ical laboratory parameters 
x Site initiation visit 
x Routine site monitoring 
x Ongoing site communica tion and training 
x Ongoing oversight by [CONTACT_3211]’s designated CRO  monitors of safety parameters and 
adherence to selection criteria 
x Data management quality control checks 
x Continuous data acquisition and cleaning 
x Quality control check of th e clinical study report (CTR) 
x To avoid interobserver variability, every ef fort should be made to ensure that the 
same individual who made the initial baseli ne determinations completes all efficacy 
and safety evaluations 
In addition, periodic audits can be performed as specified in Section [IP_ADDRESS]. 
When audits or inspections are conducted, access must be auth orized for all study-related 
documents including medical hist ory and concomitant medication documentation to authorized 
sponsor’s representatives a nd regulatory authorities. 
10.1.8. Source Documents 
x Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site. 
x Data entered in the eCRF that are tr anscribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The investigator may need to re quest previous medical reco rds or transfer records, 
depending on the study. Also, current me dical records must be available. 
x Definition of what constitutes source data can be found in the da ta management plan. 
x The investigator must maintain accurate documentation (source data) that supports 
the information entered in the eCRF. 
x Study monitors will perform ongoing source da ta verification to confirm that data 
entered into the eCRF by [CONTACT_113640] s ite personnel are accurate, complete, and 
verifiable from source documents; that the sa fety and rights of pa rticipants are being 
protected; and that the st udy is being conducted in accord ance with the currently 
approved protocol and any other study ag reeme n
 ts, ICH GCP, and all applicable 
regulatory requirements. 
Clinical Study Protocol  ARGX-113-[ADDRESS_610324] site open and will be the study start date. 
Study/Site Termination 
The sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of th e sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required docum ents and study supplies 
have been collected and a study-site closure visit has been performed. 
The investigator may init iate study-site closure at any time , provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. Reasons for the early closure of a study site by [CONTACT_941] s ponsor or investigator may include but are 
not limited to: 
For study termination: 
x Discontinuation of further study intervention development 
For site termination: 
x Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines 
x Inadequate or no recruitment (evaluated after a reasonable amount of time) of 
participants by [CONTACT_093] 
x Total number of participants in cluded earlier than expected 
If the study is prematurely termin ated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory auth orities, and any CROs us ed in the study of the 
reason for termination or suspension, as specified  by [CONTACT_1214]. The 
investigator shall promptly in form the participant and should assure appropriate participant 
therapy and/or follow-up 
10.1.10. Publication Policy 
x All information regarding AR GX-113 supplied by [CONTACT_475941] a result of this study are considered confidential and remain the 
sole property of the sponsor. The results of the study will be reported in a clinical 
study report (CSR). The CSR will be written in accordance with the ICH E3 guideline 
and will be submitted in accord ance with local regulations. 
x Any manuscript, abstract, other publication, pr esentation of the results, or information 
arising in connection with the study must be prepared with the sponsor and must be submitted to the sponsor fo r review and comment prior to submission for publication 
Clinical Study Protocol  ARGX-113-[ADDRESS_610325] editorial and ethi cal practice, the s ponsor will generally 
support publication of multicenter studies only in their entire ty and not as individual 
site data. In this case, a coordinating i nvestigator will be designated by [CONTACT_231692]. 
x Authorship will be determined by [CONTACT_14346]. 
  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 67  10.2. Appendix 2: Clinical Laboratory Tests 
x The tests detailed in Table [ADDRESS_610326] document their review  of each laboratory safety report. 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 68  Table 3: Protocol-Required Laboratory Tests 
Laboratory 
Assessment Parameters 
Hematology Platelet count 
Red blood cell (RBC) 
count 
Hemoglobin 
Hematocrit RBC Indices: 
Mean corpuscular 
volume (MCV) 
%Reticulocytes White blood cell count 
with differential (% and absolute numbers) 
Neutrophils 
Lymphocytes Monocytes Eosinophils Basophils 
Clinical chemistry Blood urea nitrogen 
(BUN) 
Creatinine 
Glucose (fasting for 8 
hours) 
Calcium Glycosylated 
hemoglobin (HbA1c) 
Potassium 
Sodium 
Alkaline phosphatase 
(ALP)
a 
Lactate dehydrogenase (LDH) C-reactive protein (CRP) 
Aspartate 
aminotransferase (AST) 
Alanine 
aminotransferase (ALT) 
Ȗ *OXWDP\O WUDQVIHUDVH
(GGT) 
Bilirubin, total and 
direct 
Albumin  Cholesterol: 
Total LDL 
HDL 
Triglycerides 
International 
Normalized Ratio (INR) 
Activated Partial 
Thromboplastin Time (aPTT) 
Routine urinalysis Specific gravity 
pH, glucose, protein, blood, ketones,  bilirubin, nitrite, leukocyte esterase by 
[CONTACT_475942] (hCG) pregnancy test 
(for female participants of childbearing potential) 
Microscopic evaluation 
Screening tests Virology: HIV 1&2 screen/p24 antigen,  hepatitis B core, hepatitis B surface, 
and hepatitis be surface antigen; and hepatitis C antibody, SARS-CoV-[ADDRESS_610327] (for female participants of 
childbearing potential) Total immunoglobulin (IgG) levels AChR-Ab serology 
Follicle-stimulating hormone (FSH ) (for female participants) 
a If alkaline phosphatase is elevated, consider fractioning. 
  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 69  10.3. Appendix 3: Total Blood Volume Co llected From Each Participant 
The maximum amount of blood collected from  each participant is 350 mL. Repeat or 
unscheduled samples may be taken for safety reasons or technical issues with samples. 
  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 74  10.5. Appendix 5: Contraceptive and Barrier Guidance 
10.5.1. Definitions 
Women of Childbearing Potential (WOCBP) 
Women in the following categories are considered WOCBP (fertile): 
1. Following menarche 
2. From the time of menarche until becomi ng postmenopausal unless permanently sterile 
(see below) 
x A postmenopausal state is defined as no mens es for 12 months without an alternative 
medical cause. 
 A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not usi ng hormonal contraception or hormonal 
replacement therapy (HRT). However,  in the absence of 12 months of 
amenorrhea, confirmation with more th an 1 FSH measurement is required.  
 Females on HRT and whose menopausal status is in doubt will be required to use 
[ADDRESS_610328] discontinue 
HRT to allow confirmation of postmenopaus al status before study enrollment. 
x Permanent sterilization me thods (for the purpose of  this study) include: 
 Documented hysterectomy 
 Documented bilateral salpi[INVESTIGATOR_1656] 
 Documented bilateral oophorectomy 
 For individuals with permanent infertility due to an alternate medical cause other 
than the above, (eg, Mullerian agen esis, androgen insensitivity, gonadal 
dysgenesis), investigator di scretion should be applied to  determining study entry 
Note:  Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or  medical history interview. 
x If fertility is unclear (eg, am enorrhea in adolescents or at hletes) and a menstrual cycle 
cannot be confirmed before first dose of study intervention, additional evaluation 
should be considered. 
Woman of Nonchildbearing Potential (WONCP) 
Women in the following categories are considered WONCBP: 
1. Premenopausal female with permanent in fertility due to 1 of the following: 
a. Documented hysterectomy 
b. Documented bilateral salpi[INVESTIGATOR_1656] 
c. Documented bilateral oophorectomy 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 75  d. For individuals with permanent infertility due  to an alternate medical cause other than 
the above (eg, Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), 
investigator discretion should be a pplied to determining study entry 
Note : Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or  medical history interview. 
1. Postmenopausal female 
a. A postmenopausal state is defined as no mens es for 12 months without an alternative 
medical cause. 
 A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not usi ng hormonal contraception or HRT. 
However, in the absence of 12 months of amenorrhea, confirmation with more 
than 1 FSH measurement is required. 
 Females on HRT and whose menopausal status is in doubt must discontinue HRT 
to allow confirmation of postmenopausal status before study enrollment. 
Contraception Guidance 
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE: 
Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year when used 
consistently and correctly.  
Implantable progestogen-only hormone contraception associat ed with inhibiti on of ovulationc 
Intrauterine device (IUD) 
Intrauterine hormone-releasing system (IUS)c 
Bilateral tubal occlusion 
Azoospermic partner (vasectomized or due to a medical cause) 
Azoospermia is a highly effective contraceptive method provided that the partner is the sole sexual partner of the 
woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly 
effective method of contraception should be used . Spermatogenesis cycle is approximately 90 days.  
Note: documentation of azoospermia for a male participan t can come from the site personnel’s review of the 
participant’s medical records, medical examination, or medical history interview. 
Highly Effective Methodsb That Are User Dependent Failure rate of <1% per year when used consistently 
and correctly.  
Combined (estrogen- and progestoge n-containing) hormonal contraception associated with inhibition of 
ovulationc 
oral 
intravaginal transdermal 
injectable 
Progestogen-only hormone c ontraception associated with  inhibition of ovulationc 
oral 
injectable 
Sexual abstinence 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 76  CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE: 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant. 
Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Male 
condom and female condom should not be used to gether due to risk of failure from friction 
a Contraceptive use by [CONTACT_211310]. 
b Failure rate of <1% per year when used consistently and correctly. Typi[INVESTIGATOR_159831]. 
c Male condoms must be used in addition to hormonal cont raception. If locally required,  in accordance with Clinical 
Trial Facilitation Group (CTFG) guid elines, acceptable contraceptive methods are limited to those which inhibit 
ovulation as the primary mode of action. 
   
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 78    
 
 
Data management and biostatistics 
Belgium  
 
 
 
Drug safety reporting 
[LOCATION_002]  
 
 
 
  

Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 79  10.7. Appendix 7: Possible Adaptations to Study Protocol During the 
COVID-19 Pandemic 
During the coronavirus diseas e-2019 (COVID-19) pandemic, study sites and participants are 
facing unprecedented challenges. As a result of this crisis, the sponsor has considered changes 
that are necessary to protect the safety of the pa rticipants as well as the site staff, while still 
evaluating the noninferiority of efgartigimod PH20 SC as compared to ef gartigimod IV. All sites 
and participants will follow local regulations and guidance regarding pr eventing the spread of 
COVID-19.  
The risk assessment, risk mitigat ion plan, and changes that may o ccur in response to an increase 
in COVID-19 cases is describe d in the following sections. 
10.7.1. COVID-19 Risk Assessment for Participant Safety 
Efgartigimod administration results in the re duction of all immunoglobulin G (IgG) subtypes, 
potentially hindering immune response and incr easing the risk of all infections, including 
COVID-19. However, efgartigimod does not affect  the levels of other immunoglobulin subtypes, 
such as IgA and IgM. Also, prev ious studies have shown that the maximum mean reduction of 
total IgG ranges from 60% to 70% and total IgG le vels return to baseline within a few weeks of 
stoppi[INVESTIGATOR_475900]. Fu rthermore, other elements of  the immune system are not 
impacted by [CONTACT_475943]. The doses used in study ARGX-113-[ADDRESS_610329] been 
administered to over 250 particip ants, including healt hy volunteers and patient s with generalized 
myasthenia gravis (gMG), immune thrombocytopen ia (ITP), and pemphigus, with no infection-
related safety concerns identified. Theref ore, despi[INVESTIGATOR_475901], efgartigimod treatment  is not expected to increas e the risk of severe acute 
respi[INVESTIGATOR_190276] s 2 (SARS-CoV-2) infection or  developi[INVESTIGATOR_35910]-19 in 
participants.  
10.7.2. COVID-19 Risk Mitigation 
All participants with clinically significant uncontr olled infections, malignancies, recent surgeries, 
and/or the presence of certain viral infections are excluded (see Section 5.2 ). The screening tests 
include a test for SARS-CoV-[ADDRESS_610330] to structured sa fety reporting and a deta iled questionnaire, so a 
participant contracting COVID-19 w ould be recorded as an AESI. 
During the entire study the sites will implement all recommen dations issued by [CONTACT_475944]-19 (eg, so cial distancing, disinfection, 
hygiene, face mask requirements, and use of pers onal protection equipment [PPE] by [CONTACT_6624]), 
including specific guidelines related to clinical research performed in clinical research centers.  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 80  10.7.3. Possible Changes in Study Design  Due to the COVID-19 Pandemic 
[IP_ADDRESS]. Implementation of This Appendix 
Implementation for all si tes includes social distancing where possible, PPE, and a telephone call 
before each study visit to check for COVID-19 sy mptoms. The adaptations to the visits and 
procedures described are acceptabl e alternatives to the main protocol procedures only under 
exceptional circumstances and after approval of  the sponsor and/or CRO. Approval will be 
granted based on the possibility of  participants going to the s ite and per local and/or site 
regulations. 
This appendix is intended for si tes in areas where COVID-[ADDRESS_610331] been imposed, or where there is a risk to participants or 
site staff when attending visits at the site. The duration of these changes will be agreed upon 
between the site and sponsor/CRO and can be extended based on the local epi[INVESTIGATOR_475902]. 
[IP_ADDRESS]. Testing for COVID-19 
Additional testing for COVID-19 beyond what is mandated by [CONTACT_475945] (Section 1.3) is not required during the study. However, it is recommended that 
participants who develop COVID-[ADDRESS_610332] participants prior to each visit to inquire about 
COVID-19 symptoms (ie, fever, cough, sneezing, lo ss of taste/smell, difficulties breathing/chest 
tightness) and exposure to determine if it is safe for the participan t to proceed with the visit as 
planned. If a participant tests positive for SARS-CoV-2 or has symptoms of COVID-19, he/she 
should not return to the site for visits until the inve stigator decides it is safe for the participant to 
return, based on local regulations an d guidance from th e site staff. 
[IP_ADDRESS]. Study Protocol Changes 
If the COVID-[ADDRESS_610333] participants.  
[IP_ADDRESS]. Critical Parameters to Be Collected During the Study 
All assessments should be performed as indicated in the SoA (Section 1.3 ) if possible. In the 
event that some assessments cannot be performe d due to the COVID-[ADDRESS_610334] be collected: all AE reporting, admin istration site reactions, SIB 
monitoring, IMP administration, wh o performed the administration, training and competency to 
perform self-administration, MG-A DL total score, and IgG levels  from the first visit through 
day 29. 
[IP_ADDRESS]. Mandatory Site Visits and Home Visits 
All visits must be performed at the site if possible. If adaptati ons are required due to the COVID-
[ADDRESS_610335] follow-up visit on day 29 
x EoS visit 
All other visits may be performed by [CONTACT_475946], and all activities that do not require the 
participant to be on site will be performed. 
  
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021
Efgartigimod IV and SC 
argenx BV Confidential 8210.8. Appendix 8: Interpretation of Hepatitis B Serologic Test Results 

Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 83  10.9. Appendix 9: Abbreviati ons and Definitions 
10.9.1. Definitions 
Enrolled: A participant’s, or their legally acceptable re presentative’s, agreement to participate in 
a clinical study following comp letion of the informed  consent process and screening. Potential 
participants who are screened for the purpose of determining e ligibility for the study, but do not 
participate in the study, are not considered enroll ed, unless otherwise specified by [CONTACT_760].  
Japanese participant: A participant whose parents and 4 grandparents are Japanese, who has 
the Japanese nationality, was bor n in Japan, has not lived outside  of Japan for a total of >10 
years, and currently lives in Japan. 
MG-ADL responder:  A participant who shows a decrease of at least [ADDRESS_610336] administration of IMP. QMG responder:  A participant who shows a decrease of at least [ADDRESS_610337] administration of IMP. Randomized: An enrolled participant has been randomly assigned to a treatment arm.  
10.9.2. Abbreviations 
AChE acetylcholinesterase 
AChR acetylcholine receptor 
AChR-Ab acetylcholine receptor binding autoantibodies 
ADA anti-drug antibodies 
ADL activities of daily living 
AE adverse event 
AESI adverse event of special interest 
AIDS acquired immunodeficiency syndrome 
AUC area under the serum c oncentration-time curve 
AUEC area under the effect curve 
CIOMS Council for International Or ganizations of Medical Sciences 
CL total clearance 
CL/F apparent total clearance 
Cmax maximum concentration 
Ctrough concentration observed predose 
CONSORT Consolidated Standards of Reporting Trials 
COVID-[ADDRESS_610338] 
HIV human immunodeficiency virus 
IB Investigator’s Brochure 
ICF informed consent form 
ICH International Council for Harmonisation 
ICU intensive care unit 
IRR injection and/or infusion-related reaction 
IEC Independent Ethics Committee  
Ig immunoglobulin 
IgG immunoglobulin G 
IMP investigational medicinal product 
IRB Institutional Review Board 
IRT Interactive Response Technology 
ITP immune thrombocytopenia 
ITT intention-to-treat 
IV intravenous 
IVIg intravenous immunoglobulin 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 85  MG-ADL Myasthenia Gravis Activities of Daily Living 
MGFA Myasthenia Gravis Foundation of America 
MG-QoL15r Myasthenia Gravis Qualit y of Life 15 item scale revised 
mITT modified intention-to-treat 
NAb neutralizing antibody 
NMJ neuromuscular junction 
NCI National Cancer Institute 
NSID nonsteroidal immunosuppressant 
PD pharmacodynamics 
PH20 recombinant human hya luronidase PH20 (rHuPH20) 
PHQ Patient Health Questionnaire 
PK pharmacokinetics 
PLEX plasma exchange 
PPE personal protective equipment 
PR atrioventricular node delay interval 
QMG Quantitative Myasthenia Gravis 
QoL quality of life 
QRS duration of ventricular depolarization 
QT total duration of ventricular depolarization 
QTcF rate-corrected QT intervals using Fridericia’s formula 
RR time between heart beats 
SAE serious adverse event 
SAP statistical analysis plan 
SARS-CoV-[ADDRESS_610339] Operating Procedures 
S[LOCATION_003]R suspected unexpected  serious adverse reaction 
TEAE treatment-emergent adverse event 
WOCBP women of childbearing potential 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 86  WONCBP women of nonchildbearing potential 
Clinical Study Protocol  ARGX-113-2001 v2.0 02 Jul 2021 
Efgartigimod IV and SC 
argenx BV Confidential 87   REFERENCES
Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle
Nerve  2008;37:141-149.
Wendell LC, Levine JM. Myasthenic crisis. Neurohospi[INVESTIGATOR_8384].  2011;1(1):16–22.
Gilhus, NE. Myasthenia gravis. Brain. N Engl J Med  2016; 375(26):2570-2581.
Efgartigimod (ARGX-113)  Investigator’s Brochure , version 9.0, November 2020.
Recombinant human hyaluronidase PH20 (rHuPH20) Investigator’s Brochure, version
7.0, January 2019.
Shpi[INVESTIGATOR_83868] O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and
trastuzumab (Herceptin) using hyaluronidase. Br J Cancer.  2013;109(6):1556-1561.
Neuenschwander B, Capkun-Niggli G, Branson M, Spi[INVESTIGATOR_59898]. Summarizing
historical information on controls in clinical trials. Clin Trials.  2010;7(1):5-18.
FDA. Immunogenicity testing of therapeutic protein products—developi[INVESTIGATOR_475903]-drug antibody detection. Guidance for Industry. U.S. Food and DrugAdministration website, 2019. Available at:https://www.fda.gov/media/119788/download